COMPOUNDS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS

Abstract

The present invention relates to compositions and methods for their use in the treatment of fungal infections and diseases.

Description

COMPOUNDS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS REFERENCE TO RELATED APPLICATIONS This application claims the benefits of US Provisional Application No. 62 / 725,971, filed August 31, 2018, which is considered a part of and is incorporated by reference in this application. BACKGROUND OF THE INVENTION Fungi infect humans and are a major cause of human health problems. The fungi also infect plants and cause huge productivity losses in agriculture. The present disclosure relates generally to the treatment and / or prevention of infections and fungal diseases. BRIEF DESCRIPTION OF THE INVENTION In one aspect, what is provided herein is a pharmaceutical composition, comprising: (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral dosage or administration. In another aspect, a pharmaceutical composition is provided, comprising: (i) fine particles of the compound of Formula (I); or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral administration or dosage or in an inhalation dosage form. In some embodiments, the particles are micronized. In some embodiments, the particles have a particle size between about μιη and about 750 pm. In some embodiments, at least about 10% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 20% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 30% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 40% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 50% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 60% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 70% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 80% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 90% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 95% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, the particles are micronized. In some embodiments, at least about 10% of the particles have a particle size between about 1 pm and about 750 nm. In some embodiments, at least about 20% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 30% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 40% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 50% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 60% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 70% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 80% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 90% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 95% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, the dosage form is a self-microemulsifying drug delivery system (SMEDDS). In some embodiments, the dosage form is a self-emulsifying drug delivery system (SEDDS). In some embodiments, the dosage form is a suspension or a solution. In some embodiments, the dosage form is a nanosuspension. In some embodiments, the dosage form is a solid dosage form. In some embodiments, the dosage form is a spray dried dispersion dosage form. In some embodiments, the dosage form is a hot granulation dosage form. In some embodiments, the dosage form is a hot extrusion dosage form. In some embodiments, the dosage form is a microprecipitated bulk powder (MBP) dosage form. In some embodiments, the dosage form is a liquid. In some embodiments, the dosage form is a suspension, solution, syrup, or elixir. In some embodiments, the pharmaceutical composition is in a dosage form for oral dosage or administration. In some embodiments, the dosage form is a tablet or a capsule. In some embodiments, the tablet or capsule is enteric coated. In some embodiments, the dosage form is a tablet. In some embodiments, the tablet is a floating osmotic tablet. In some embodiments, the capsule is a liquid-filled hard capsule. In some embodiments, the capsule is a soft gelatin capsule. In some embodiments, the dosage form is a modified release dosage form. In some embodiments, the modified release dosage form is a delayed release dosage form, an extended release (ER) dosage form, or a directed release dosage form. In some embodiments, the ER dosage form is a sustained release (SR) dosage form or a hbh7nn / Lznz / E / Yli (CR) controlled release dosage form. In some embodiments, the dosage form is an immediate release dosage form. In some embodiments, the pharmaceutical composition comprises between about 10 mg and about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 50 mg and about 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, it is between about 50 mg and about 150 mg, between about 150 mg and about 250 mg, between about 250 mg and about 350 mg, between about 350 mg and about 450 mg, between about 450 mg and about 550 mg, from about 550 mg to about 650 mg, from about 650 mg to about 750 mg, from about 850 mg to about 950 mg, or from about 950 mg to about 1050 mg of a compound of Formula (I), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, or about 500 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg of a compound of Formula (I), or an isotopic, tautomeric variant. , pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutically acceptable excipient is a filler, disintegrant, binder, lubricant, or any combination thereof. In some embodiments, the pharmaceutically acceptable excipient is microcrystalline cellulose, pregelatinized starch, povidone, magnesium stearate, colloidal silicon dioxide, or any combination thereof. In some embodiments, the pharmaceutical composition is stable for up to 36 months at a temperature between about 2°C and about 25°C. In some embodiments, the pharmaceutical composition is stable for a period of between about 24 and about 36 months at a temperature between about 2°C and about 8°C. In some embodiments, the pharmaceutical composition is stable for up to 36 months at about 2°C to about 25°C when stored as a solid. In some embodiments, the pharmaceutical composition is stable for a period of between about 24 and about 36 months at about 2°C to about 8°C when stored as a solid. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt. , solvate, or hydrate thereof. In one aspect, a pharmaceutical composition is provided herein, comprising: (i) the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for dosage or administration by injection. In some embodiments, the pharmaceutical composition is in a dosage form for intravenous (IV) injection or infusion, or intramuscular, subcutaneous, or intradermal injection. In some embodiments, the pharmaceutical composition is in a dosage form for IV injection or infusion. In some embodiments, the dosage form is an IV dosage form. In some embodiments, the pharmaceutical composition is a solution. In some embodiments, the dosage form comprises a cosolvent. In some embodiments, the cosolvent comprises PEG200, PEG300, PEG400, PEG600, propylene glycol, ethanol, polysorbate 20, polysorbate 80, cremophor, glycerin, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), ferf-butanol, or any of its combinations. In some embodiments, the dosage form further comprises an oil. In some embodiments, the oil comprises sesame oil, soybean oil, vegetable oil, poppy oil, safflower oil, or combinations thereof. In some embodiments, the dosage form further comprises a buffer solution. In some embodiments, the IV dosage form further comprises a buffer solution. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is potassium phosphate. In some embodiments, the potassium phosphate is monobasic or dibasic. In some embodiments, the pharmaceutical composition has a pH between about 2.5 and about 11.0. In some embodiments, the pharmaceutical composition has a pH between about 2.5 and about 5.0 or between about 6.5 and about 10.5. In some embodiments, the pharmaceutical composition has a pH between about 2.5 and about 4.5 or between about 7.0 and about 9.0. In some embodiments, the pH of the pharmaceutical composition that is formulated for IV administration is adjusted with hydrochloric acid and / or sodium hydroxide. In some embodiments, the pharmaceutical composition comprises between about 5 mg / mL and about 250 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of hbh7nn / Lznz / E / Yli himself. In some embodiments, the pharmaceutical composition comprises between about 10 mg / mL and about 50 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 20 mg / mL and about 40 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, or about 30 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at a temperature between about -20°C and 8°C. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about -20°C. In some embodiments, the pharmaceutical composition comprises approximately 20 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystalline, microcrystalline, amorphous, or lyophilized. In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystal clear In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is amorphous. In some embodiments, the compound of Formula (I) or an isotopic vanant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is lyophilized. In some embodiments, the pharmaceutical composition is substantially free of impurities. In some embodiments, the pharmaceutical composition is at least about 90% pure. In some embodiments, the pharmaceutical composition is at least about 95% pure. In some embodiments, the pharmaceutical composition is at least about 96% pure. In some embodiments, the pharmaceutical composition is at least about 97% pure. In some embodiments, the pharmaceutical composition is at least about 98% pure. In some embodiments, the pharmaceutical composition is at least about 99% pure. In some embodiments, the pharmaceutical composition is at least about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%, or about 100% pure. In some embodiments, the pharmaceutical composition comprises up to about 10% (w / w) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 10% (w / w), about 9% (w / w), about 8% (w / w), about 7% (w / w), about 6 % (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), or about 1% (w / w). p) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), or about 1% (w / w) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 0.9% (w / w), about 0.8% (w / w), about 0.7% (w / w), about 0.6% (w / w), about 0.5 % (w / w), about 0.4% (w / w), about 0.3% (w / w), about 0.2% (w / w), or about 0.1% (w / w) of at least one impurity. In some embodiments, the impurity is a degradant. In some embodiments, the impurity is: frfrfrznn / Lznz / Ε / γΐΛΐ or any of their combinations. In some embodiments, the impurity is: hbh7nn / Lznz / E / Yli In some embodiments, the pharmaceutical composition comprises up to about 4.0% (w / w) total impurities. In some embodiments, the pharmaceutical composition comprises up to about 0.5% (w / w) of any particular impurity. In some embodiments, the pharmaceutical composition comprises up to about 1.5% (w / w) of the compound: In another aspect, a combined composition is provided, comprising: (i) the compound of Formula (I); or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one antifungal agent. In some embodiments, the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof. In some embodiments, the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole. In some embodiments, the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin. In one aspect, the invention provides a combined composition, comprising: hbhznn / ιζηζ / Ε / γι (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a compound of Formula (II) (ii), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the combined composition further comprises at least one pharmaceutically acceptable excipient. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are both crystalline. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 10:1. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 9:1 and about 9.99:0.01. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 9.5:0.5 and about 9.9:0.1. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of about 9:1, about 9.1:0.9, about 9.2:0.8, about 9.3:0.7, about 9.4:0.6, about 9.5:0.5, about 9.6:0.4, about 9.7:0.3, about 9.8:0.2, or about 9.9:0.1. In one aspect, the invention provides a method of treating or preventing a fungal infection or disease, comprising administering to a subject in need thereof a therapeutically effective amount of any of the pharmaceutical compositions or combination compositions as described herein. In some embodiments of the methods of the invention, between about 10 mg and about 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered to the subject. . In some embodiments of the methods of the invention, between about 10 mg and about 2,400 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered to the subject. . In some embodiments of the methods of the invention, the subject is administered about 10 mg, about 30 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,200 mg, about 1,500 mg, about 1,800 mg, about 2,000 mg, about 2,100 mg, about 2,400 mg, about 2,500 mg, about 3,000 mg, about 4,000 mg, about 5,000 mg, about 6,000 mg, about 7,000 mg, or about 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered about 40 mg, about 50 mg, about 100 mg, about 200 mg, about 250 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, or about 900 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, about 600 mg, about 700 mg, about 800 mg, about 900 mg, 1,000 mg, about 2,000 mg, or about 3,000 mg of the compound of Formula (I), or a isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject daily. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject once per day, twice per day, three times per day, or four times per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject once per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject twice per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject for a period of up to about 12 weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of at least one week. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of at least two weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject for a period of up to about 2 weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of one week, two weeks, 6 weeks, 12 weeks, 24 weeks, 48 ​​weeks, or 52 weeks. In some embodiments of the methods of the invention, the subject is administered between about 10 mg and about 8,000 mg of the compound of the Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, or about 2,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of approximately 20 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, approximately 12 hours, approximately 18 hours, or approximately 24 hours by IV infusion. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of up to about 3 hours by IV infusion. In some embodiments of the methods of the invention, the subject is administered a loading dose followed by a maintenance dose. In some embodiments of the methods of the invention, the loading dose comprises between about 1,000 mg and about 8,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate. of the same. In some embodiments of the methods of the invention, the maintenance dose comprises between about 600 mg and about 2,400 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate. of the same. In some embodiments of the methods of the invention, the loading dose is between about 1,000 mg and about 2,000 mg. In some embodiments of the methods of the invention, the loading dose is administered over a period of about 2 and about 3 hours by IV infusion. In some embodiments of the methods of the invention, the loading dose is administered twice during the first day of treatment. In some embodiments of the methods of the invention, the second loading dose is administered approximately 9 hours after the first loading dose. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1,000 mg of a compound of Formula (I), or a variant. isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the maintenance dose comprises about 800 mg or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate is administered to the subject. , or hydrate thereof. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the same. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the itself and is administered orally. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the It is administered over a period of approximately 1 hour and approximately 3 hours by IV infusion. In some embodiments of the methods of the invention, the method of any of embodiments 157-164, wherein about 600 mg of a compound of Formula (I), or an isotopic variant, tautomeric, pharmaceutically acceptable salt , solvate, or hydrate thereof is administered over a period of approximately 3 hours by IV infusion. In some embodiments of the methods of the invention, the maintenance dose is administered once per day. In some embodiments of the methods of the invention, the maintenance dose is administered once per day beginning on the second day of treatment. In some embodiments of the methods of the invention, about 600 mg or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered throughout. over a period of approximately 3 hours by IV infusion starting on the second, third, or fourth day of treatment. In some embodiments of the methods of the invention, about 800 mg or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered via the oral from the second third or fourth day of treatment. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the same. In some embodiments of the methods of the invention, the subject is administered approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of about 1 hour and about 3 hours by IV infusion and / or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and administered orally . In some embodiments of the methods of the invention, the maintenance dose is administered once per day. In some embodiments of the methods of the invention, the maintenance dose is administered once per day beginning on the second day of treatment. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of approximately 3 hours by IV infusion. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of approximately 3 hours by IV infusion from the second day of treatment. In some embodiments of the methods of the invention, approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered orally from the fourth day of treatment. In some embodiments of the methods of the invention, the fungal infection is caused by an invasive fungus. In some embodiments of the methods of the invention, the method further comprises administering to the subject at least one antifungal agent in combination with the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomeric, pharmaceutically acceptable, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof. In some embodiments of the methods of the invention, the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole. In some embodiments of the methods of the invention, the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin, or combinations thereof. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously, approximately simultaneously, or sequentially, in any order. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously or approximately simultaneously. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered sequentially. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered before the antifungal agent In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered after the antifungal agent. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a fungus Aspergillus fumigatus, Blastomyces, Ajellomyces, Candida, Coccidioides, Cryptococcus, Histoplasm, Rhizopus Muco, Cunninghamell, Apophysomyces, Absidi, Saksenaea, Entomophthora, Conidiobolus, Basidiobolus, Sporothrix, Pneumocystis, Talaromyces, Asclepias, Fusarium, Scedosporium or by a fungus of the order Mucorales, or any of their combinations. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a Cryptococcus, Aspergillus, Candida, Fusarium, Scedosporium fungus, or by a fungus of the order Mucorales, or any combination thereof. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a fungus Aspergillus fumigatus, Aspergillus flavus, Blastomyces dermatitidis, Ajellomyces dermatitidi, Candida albican, Candida glabrata, Candida rugosa, Candida auris, Coccidioides immitis, Coccidioides posadasii, Cryptococcus neoformans, Cryptococcus gattii, Histoplasma capsulatum, Rhizopus stolonifer, Rhizopus arrhizus, Mucor indicus, Cunninghamella bertholletiae, Apophysomyces elegans, Absidia spp., Saksenaea spp., Rhizomucor pusillus, Entomophthora spp., Conidiox bertholletiae spp., Basidia spp. stis jirovecii , Talaromyces marneffei, Asclepias albicans, Fusarium solani, Scedosporium apiospermum, Rhizomucor pusillus, or any of their combinations. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a Cryptococcus fungus or a Candida fungus. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a fungus Cryptococcus neoformans, Cryptococcus gattii, or Candida auris. In some embodiments of the methods of the invention, the fungal infection or disease is resistant to the azole and / or resistant to the echinocandin. In some embodiments of the methods of the invention, the subject is immunocompromised. In some embodiments of the methods of the invention, the subject is infected with HIV / AIDS or has cancer. In some embodiments of the methods of the invention, the subject has cancer. In some embodiments of the methods of the invention, the cancer is acute myeloid leukemia (AML). In some embodiments of the methods of the invention, the subject is neutropenic. In some embodiments of the methods of the invention, the subject is or has been undergoing chemotherapy treatment for cancer. In some embodiments of the methods of the invention, the subject is or has been under corticosteroid treatment. In some embodiments of the methods of the invention, the subject is or has been under treatment with TNF inhibitors. In some embodiments of the methods of the invention, the subject is the recipient of a transplant. In some embodiments of the methods of the invention, the infection or fungal disease is in the subject's bloodstream. In some embodiments of the methods of the invention, the subject has a reduced fungal colony count in the lungs after administration of the pharmaceutical composition. In some embodiments of the methods of the invention, the plasma concentration vs. time curve of the compound of Formula (I) in the subject has a tmax of less than between about 30 minutes and about 180 minutes. In some embodiments of the methods of the invention, the subject has a maximum plasma concentration (Cmax) of between about 12,000 ng / mL and about 25,000 ng / mL of the compound of Formula (I). Incorporation As Reference hbh7nn / ί7Π7 / Β / ΥΙ All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as they would have been if each such publication, patent, or patent application had been mentioned as such. BRIEF DESCRIPTION OF THE FIGURES Figure 1A-1B Geometric mean Compound 1A plasma concentrations after IV infusion of between 10 and 1000 mg of Compound 1 over 3 hours to healthy subjects — linear (Figure 1A) and semi-logarithmic (Figure 1B) axes. Figure 2A-2B Geometric mean Compound 1A plasma concentrations after IV infusion of 1000 mg over 0.5 to 3 hours to healthy subjects — linear (Figure 2A) and semi-logarithmic (Figure 2B) axes. Figure 3A-3B Geometric mean Compound 1A plasma concentrations after IV infusion of 50, 150, 300, and 600 mg Compound 1 over 3 hours qd χ 14 days to healthy subjects — linear axes (Figure 3A) and semi-logs (Figure 3B) Figure 4A-4B Geometric mean Compound 1A plasma concentrations after IV infusion of a 1000 mg Compound 1 loading regimen over 2 hours at 0 and 9 hours on Day 1 followed by 600 mg over 1 hour qd χ 6 days, days 2 to 7, to healthy subjects — linear (Figure 4A) and semi-log (Figure 4B) axes Figure 5A-5B Geometric mean Compound 1 plasma concentrations after IV infusion of 10 to 350 mg of Compound 1 over 3 hours and 1000 mg over 0.5 to 3 hours to healthy subjects — linear axes (Figure 5A) and 21 semi-logs (Figure 5B). Figure 6A-6B Geometric mean Compound 1 plasma concentrations after IV infusion of 50, 150, 300, and 600 mg Compound 1 over 3 hours QD χ 14 days to healthy subjects — linear axes (Figure 6A) and semilogarithmic (Figure 6B). Figure 7A-7B Geometric mean Compound 1 plasma concentrations after IV infusion of a 1000 mg Compound 1 loading regimen over 2 hours at 0 and 9 hours on day 1 followed by 600 mg at over 1 hour qd χ 6 days, days 2 to 7, to healthy subjects — linear (Figure 7A) and semi-logarithmic (Figure 7B) axes. Figure 8A-8B Geometric mean Compound 1A plasma concentrations after intravenous infusion of 200 mg of Compound 1 over 3 hours and oral doses between 100 and 500 mg to healthy subjects under fasting conditions — linear axes ( Figure 8A) and semi-logarithmic (Figure 8B). Figure 9A-9B Geometric mean of Compound 1A plasma concentrations following 400 mg oral doses of Compound 1 to healthy subjects under fasting and non-fasting conditions — linear (Figure 9A) and semi-logarithmic (Figure 9B) axes. Figure 10A-10B Geometric mean Compound 1A plasma concentrations after 500 and 1000 mg oral doses of Compound 1 QD χ 14 days to non-fasting healthy subjects — linear (Figure 10A) and semi-logarithmic (Figure 10B) axes. Figure 11 Dissolution profile for Compound 1 400 mg tablets. frfrfrznn / Lznz / Ε / γΐΛΐ DETAILED DESCRIPTION OF THE INVENTION Provided herein are, for example, compositions for the treatment and / or prevention of an infection or fungal disease. Also provided herein are, for example, methods of treating and / or preventing a fungal infection or disease. Definitions Abbreviations used herein have their usual meaning within the chemical and biological arts. The structures and chemical formulas set forth herein are constructed in accordance with standard rules of chemical valence known in the chemical arts. The term "tautomer" as used herein refers to one of two or more structural isomers that exist in equilibrium and that readily interconvert from one isomeric form to another. It will be apparent to those of skill in the art that certain compounds of this invention may exist in tautomeric forms, where all such tautomeric forms of the compounds are within the scope of the invention. Unless otherwise indicated, the structures depicted herein also include compounds that differ only by the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen with a deuterium or tritium, or the replacement of a carbon with 13C or 14C-enriched carbon, are within the scope of this invention. The compounds of the present invention may also contain unnatural atomic isotope ratios on one or more of the constituent atoms of said compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as, for example, tritium (3H), iodine-125 (125l), or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention. The term "isotopic variant" refers to a compound that contains an unnatural proportion of an isotope on one or more of the constituent atoms of said compound. In some embodiments, an "isotopic variant" of a compound contains unnatural hbh7nn / Lznz / E / Yli ratios of one or more isotopes, including, but not limited to, hydrogen (1H), deuterium (2H), tritium (3H), carbon-11 (11C), carbon-12 (12C), carbon-13 (13C), carbon-14 (14C), nitrogen-13 (13N), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-14 (14O), oxygen-15 (15O), oxygen-16 (16O), oxygen-17 (17O), oxygen-18 (18O), fluorine-17 (17F), fluorine-18 ( 18F), Phosphorus-31 (31P), Phosphorus-32 (32P), Phosphorus-33 (33P), Sulfur-32 (32S), Sulfur-33 (33S), Sulfur-34 (34S), Sulfur-35 (35S) ), sulfur-36 (36S), chlorine-35 (35CI), chlorine-36 (36CI), chlorine-37 (37CI), bromine-79 (79Br), bromine-81 (81Br), iodine-123 (123l) , iodine-125 (125l), iodine-127 (127l), iodine-129 (129l), and iodine-131 (131l). In some embodiments, an "isotopic variant" of a compound is in a stable state, ie, non-radioactive. In some embodiments, an "isotopic variant" of a compound contains unnatural ratios of one or more isotopes, including, but not limited to, hydrogen (1H), deuterium (2H), carbon-12 (12C), carbon-13 (13C), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-16 (16O), oxygen-17 (17O), oxygen-18 (18O), fluorine-17 (17F), phosphorus -31 (31P), sulfur-32 (32S), sulfur-33 (33S), sulfur-34 (34S), sulfur-36 (36S), chlorine-35 (35CI), chlorine-37 (37CI), bromine- 79 (79Br), bromo-81 (81Br), and iodo-127 (127l). In some embodiments, an "isotopic variant" of a compound is in an unstable, ie, radioactive, form. In some embodiments, an "isotopic variant" of a compound contains unnatural ratios of one or more isotopes, including, but not limited to, tritium (3H), carbon-11 (11C), carbon-14 (14C ), Nitrogen-13 (13N), Oxygen-14 (14O), Oxygen-15 (15O), Fluorine-18 (18F), Phosphorus-32 (32P), Phosphorus-33 (33P), Sulfur-35 (35S), Chlorine -36 (36CI), iodine-123 (123l), iodine-125 (125l), iodine-129 (129l), and iodine-131 (131l). It is to be understood that, in a compound as provided herein, any hydrogen can be 2H, for example, or any carbon can be 13C, for example, or any nitrogen can be 15N, for example, or any oxygen can be 18O, for example. , when possible according to the judgment of a person with experience in the art. In some embodiments, an "isotopic variant" of a compound contains unnatural amounts of deuterium (D). It should be noted that, throughout the application, alternatives are written as Markush groups, eg, each amino acid position containing one more possible amino acid. It is specifically contemplated that each member of the Markush group is to be considered separately, thereby encompassing another embodiment, and the Markush group is not to be read as an individual unit. The terms "a" or "an," as used herein designate one or more elements. Furthermore, the phrase "substituted with one [an]," as used herein, means that the specified group may be substituted with one or more of any or all of the substituents mentioned. For example, when a group, such as an alkyl or hbh7nn / LZnZ / B / Yli heteroaryl group, is "substituted with unsubstituted C1-C20 alkyl, or unsubstituted 2-20 membered heteroalkyl," the group may contain one or more unsubstituted C1-C20 alkyls, and / or one or more unsubstituted 2-20 membered heteroalkyls. The term "acceptable" with respect to a formulation, composition, or ingredient, as used herein, means that it does not have a persistent deleterious effect on the general health of the subject being treated. The term "pharmaceutically acceptable salt" as used herein includes both basic and acid addition salts, that is, including salts of the active compounds that are prepared with relatively non-toxic acids or bases, depending on the particular substituents found. in the compounds described herein. When the compounds of the present invention contain relatively acid functionalities, basic addition salts can be obtained by contacting the neutral form of said compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable basic addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts, or a similar salt. When the compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of said compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as salts derived from relatively non-toxic organic acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, italic, benzenesulfonic, ptolylsulfonic, citric, tartaric, oxalic, methanesulfonic acids, and the like . Also included are salts of amino acids such as arginate and the like, and salts of organic acids such as glucuronic or galacturonic acids and the like (see, for example, Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted to basic or acid addition salts, or to exist as zwitterions. Therefore, the compounds of the present invention can exist as salts, such as with pharmaceutically acceptable acids. The present invention includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (for example, (+)-tartrates, (-)-tartrates, or mixtures of including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid salts, and quaternary ammonium salts (eg, methyl iodide, ethyl iodide, and the like). These salts can be prepared by methods known to those of skill in the art. The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound may differ from the various salt forms in different physical properties, such as solubility in polar solvents. In some embodiments, the compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted to their basic or acid addition salts. Neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compounds differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but, unless specifically indicated, the salts disclosed herein are equivalent to the parent form. of the compound for the purposes of the present invention. In addition to salt forms, the present invention provides compounds that are in a prodrug form. Prodrugs of the compounds as described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Prodrugs of the compounds as described herein can be converted in vivo after administration. In addition, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment, such as, for example, by a suitable enzyme or chemical reagent. Certain compounds of the present invention may exist as unsolvated forms, as well as solvated forms, including hydrated forms. In general, solvated forms are equivalent to unsolved forms and are encompassed within the scope of the present invention. Certain compounds of the present invention can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are included within the scope of the present invention. hbh7nn / ί7Π7 / Β / ΥΙ "Pharmaceutically acceptable carrier" and "pharmaceutically acceptable carrier" refer to a substance that aids in the administration of a compound and its absorption by a subject, and may be included in the compositions herein. invention without causing a significant toxicologically adverse effect in the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, and colorants, and the like. Said preparations can be sterilized, and if desired, can be mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffer solutions, colorants, and / or aromatic substances and the like. which do not react deleteriously with the compounds of the invention. Those of skill in the art will recognize that there are other pharmaceutical excipients that are useful with the present invention. The term "preparation" includes the formulation of the active compound with encapsulating material such as a vehicle that provides a capsule within which the active component, with or without other vehicles, is surrounded by, and therefore associated with, the vehicle. . Similarly, caches and pickups are included. Tablets, powders, capsules, pills, caches, and lozenges can be used as solid dosage forms suitable for oral administration. The terms "disease" or "condition" refer to a state of well-being or state of health of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a fungal infection. In certain other cases, "fungal infection or disease" refers to fungal infections or diseases in humans, including a Cryptococcus, Aspergillus, or Candida disease or infection. As used herein, the terms "fungal infection" or "fungal disease" refer to a disease caused by pathogenic fungi. The fungal infection can be an opportunistic or primary infection and can be caused by fungi that are yeasts and / or molds. The terms "treat" or "treatment" refer to any indication of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abolition; remission; reduction of symptoms or transformation of the lesion, pathology or condition into a more tolerable one for the patient; slowing of the rate of degeneration or decline; transformation of the end point of degeneration into less debilitating; improvement of a patient's physical or mental well-being. Treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric examinations, and / or psychiatric evaluation. The term "treat" and conjugations thereof may include the prevention of an injury, pathology, condition, or disease. In some embodiments, to treat is to prevent. In other embodiments, treatment does not include prevention. "Treat," "treatment," "palliation," or "amelioration" are used herein synonymously. These terms, as used herein (and are well understood in the art) also broadly include any strategy for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical outcomes may include, but are not limited to, alleviating or ameliorating one or more symptoms or conditions, decreasing the extent of a disease, stabilizing (ie, not worsening) the disease state, preventing transmission or spread of a disease, retard or slow the progression of a disease, improve or alleviate the state of the disease, decrease the recurrence of a disease, and a remission, either partially or completely, and in a detectable or undetectable manner. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of disease. Treatment can prevent the occurrence of a disease; inhibit the spread of the disease; alleviate the symptoms of the disease (for example, itching, swelling, burning, cough, fever, chest pain, shortness of breath), eliminate all or part of the underlying cause of the disease, shorten the duration of an illness, or make a combination of these things. "Treat" and "treatment" as used herein include prophylactic treatment. Methods of treatment include administering to a subject a therapeutically effective amount of a compound as described herein. The administering step may consist of a single administration or may include a series of administrations. The duration of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the compositions used in the treatment, or a combination of the hbhznn / ιζηζ / Β / γι themselves. It is also to be appreciated that the effective dosage of an agent used for treatment or prophylaxis may be increased or decreased over the course of a particular treatment or prophylaxis regimen. Dosage changes may result and be evident from standard diagnostic tests known in the art. In some cases, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient. The terms "prevent," "prevent," and "prevention" refer to a decrease in the occurrence of disease symptoms in a patient. The prevent or prevent step can be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur in the absence of treatment. In some embodiments, preventing refers to slowing the progression of the disease, disorder, or condition, or inhibiting the progression thereof to a harmful or otherwise unwanted state. "Patient" or "subject in need thereof" refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammalian animals including, but not limited to, fish and birds. In some embodiments, a patient is human. Treatment, as referred to herein, also refers to the systemic administration of the compounds disclosed in the present invention to any type of plant, including trees, shrubs, flowering plants, leafy plants, houseplants, ground cover and herbs, and agronomic plants (including agronomic plant crops). As used herein, "hydrates" are compounds that contain either stoichiometric or non-stoichiometric amounts of water, and, in some embodiments, are formed during the crystallization process with water. As used herein, the term "agronomic plant" refers to a plant from which all or part of it has been harvested or cultivated on a commercial scale, or which serves as an important source of food, food , fiber, or other chemical compounds. hbhznn / ιζηζ / Β / γι An "effective amount" is an amount sufficient for a compound to fulfill a stated purpose relative to the absence of the compound (for example, to achieve the effect for which the compound is administered, to treat a disease, to reduce enzyme activity, to increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which may also be referred to as a "therapeutically effective amount." A “reduction” of a symptom(s) (and the grammatical equivalents of this phrase) means to lessen the severity or frequency of the symptom(s), or to eliminate the symptom(s). A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, eg, prevent or delay the onset (or recurrence) of a lesion, disease, pathology, or condition, or reduce the likelihood of onset (or recurrence) of an injury, disease, pathology, or condition, or its symptoms. The full prophylactic effect does not necessarily occur with the administration of one dose, and may only occur after the administration of a series of doses. Therefore, a prophylactically effective amount can be administered in one or more administrations. An "activity-reducing amount," as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A "amount that disrupts function," as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and can be evaluated by those of skill in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (Volumes 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). The therapeutically effective amount can be evaluated by measuring the relevant physiological effects, and can be adjusted according to the dosage regimen and diagnostic analysis of the subject's condition, and the like. By way of example, measurement of the serum level of a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof (or, for example, a metabolite thereof) from a point in time particular after administration may be indicative of whether a therapeutically effective amount has been administered. trhhznni ίζηζ / Β / γι For any of the compounds described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of the active compound(s) that are capable of achieving the methods described herein, as measured by the methods described herein or known in the art. As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a human dose may be formulated to achieve a concentration that has been found to be effective in animals. Dosage in humans can be adjusted by monitoring the efficacy of the compounds and adjusting the dosage up or down, as described above. Dose adjustment for maximum efficacy in humans based on the methods described above and other methods is well within the capabilities of those skilled in the art. Dose adjustment to achieve the maximum therapeutic window of efficacy or toxicity in humans based on the methods described above and other methods is well within the capabilities of those skilled in the art. The term "therapeutically effective amount," as used herein, refers to that amount of therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for a given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%. , 90%, or at least 100%. Therapeutic efficacy can also be expressed as "folds" of increase or decrease. For example, a therapeutically effective amount may have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. Dosages may vary depending on the requirements of the patient and the compound being used. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose will also be determined by the existence, nature, and extent of any adverse side effects. Determination of the appropriate dosage for a particular situation is within the capabilities of the practitioner. In general, treatment is initiated with lower dosages that are less than the optimal dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances of the case is reached. The amounts and intervals between dosing can be individually adjusted to provide levels of the administered compound that are effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state. As used herein, the term "administer" means parenteral or enteral administration. Accordingly, as used herein, "administer" refers to administration including, but not limited to, oral administration, administration as a suppository, by topical contact, intravenous, intraperitoneal, intramuscular, inhalation, by nebulization, intralesional, intrathecal, intracranial, intranasal, subcutaneous, or implantation of a slow release device, eg, a mini osmotic pump, into a subject. Administration is by any route, including transmucosal (eg, buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of administration include, but are not limited to, the use of liposome formulations, intravenous infusion, transdermal patches, by the ocular route, by the otic route, etc. The term "co-administered" designates a composition as described herein that is administered at the same time, just before, or just after the administration of one or more additional therapies (eg, antifungal agent, antibacterial agent, antiviral agent, and / or chemotherapeutic agent). The compound of the invention can be administered alone or it can be co-administered to the patient. Co-administration includes simultaneous, approximately simultaneous, or sequential administration of the compound singly or in combination (more than one compound or agent). Therefore, the preparations can also be combined, when desired, with other active substances (eg to reduce metabolic degradation). The compositions of the present invention can be administered transdermally, via a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, caches, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, caches, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, solutions in water or water / propylene glycol. The compositions of the present invention may further include components to provide sustained release and / or convenience. Such components include high molecular weight anionic mucomimetic polymers, gelling polysaccharides, and finely divided drug transporter substrates. These components are presented in more detail in US Patent Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be administered as depot microspheres in the body. For example, the microspheres can be administered by transdermal injection of drug-containing microspheres, which are slowly released subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as gel formulations biodegradable and injectable (see, for example, Gao Pharm. Res. 12:857-863, 1995), or, as microspheres for oral administration (see, for example, Eyles, J. Pharm. Pharmacol. 49:669-674, 1997).In another embodiment, formulations of the compositions of the present invention can be administered through the use of liposomes that are fused to the cell membrane or are endocytosed, that is, through the use of liposome-bound receptor ligands. that bind to cell surface membrane protein receptors resulting in endocytosis Through the use of liposomes, particularly when the surface of the liposome carries receptor ligands specific to the target cells, or are otherwise targeted in preferentially to a specific organ, the administration of the compositions of the present invention can be targeted to target cells in vivo. (See, for example, Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46: 15761587, 1989). The compositions of the present invention can also be administered as nanoparticles. "Co-administer" means that a composition as described herein is administered at the same time, just before, or just after the administration of one or more additional therapies. The compounds of the invention can be administered alone, or they can be co-administered to the patient. Co-administration includes the simultaneous or sequential administration of the compounds individually or in a combination (more than one compound). The compositions of the present invention can be administered transdermally, via a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. For any compound as described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of one or more active compounds that are capable of achieving the methods described herein, as measured by the methods described herein or known in the art. As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a human dose can be formulated to achieve a concentration that has been found to be effective in animals. Dosage in humans can be adjusted by monitoring the efficacy of the compounds and adjusting the dosage up or down, as described above. Dose adjustment to achieve maximum efficacy in humans based on the methods described above, and other methods, is well within the capabilities of those skilled in the art. Dosages may vary depending on the requirements of the patient and the compound being used. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose will be determined by the existence, nature, and extent of any adverse side effects. Determination of the appropriate dosage for a particular situation is within the abilities of the practitioner. In general, treatment is initiated with lower dosages that are less than the optimal dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances of the case is reached. The amounts and intervals between dosages can be individually adjusted to provide levels of the administered compound that are effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state. Using the disclosures provided herein, an effective therapeutic or prophylactic treatment regimen can be planned that does not cause substantial toxicity and is equally effective in treating the clinical symptoms demonstrated by the particular patient. This planning should involve careful selection of the active compound taking into account factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent. The compounds described herein may be used in combination with one another, with other active agents known to be useful in the treatment of infections (eg, fungal infections). In some embodiments, co-administration includes administering an active agent at 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 2 days, 4 days, 1 week, or 1 month of a hbh7nn / ί7Π7 / Β / ΥΙ second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (eg, within approximately 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, that is, preparation of a single pharmaceutical composition that includes both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and / or adjuvant agents may be linked or conjugated to each other. In some embodiments, the compounds described herein can be combined with treatments for infections (eg, fungal infections, bacterial infections, viral infections, etc.). The compounds described herein can be administered to treat an infection or fungal disease. In this regard, the compounds disclosed in the present invention may be administered alone to treat said infections or diseases or may be co-administered with another therapeutic agent to treat said infections or diseases. The compounds disclosed in the present invention may be co-administered with an antifungal agent, such as polyenes, azoles, nucleoside analogs, echinocandins, and allylamines. "Antifungal agent" is used in accordance with its simple ordinary meaning and refers to a composition (eg, compound, drug, antagonist, inhibitor, modulator) that has antifungal properties or the ability to inhibit the growth or proliferation of fungi. In some embodiments, an antifungal agent is an agent identified herein as having utility in methods of treating fungal infections or diseases. In some embodiments, an antifungal agent is an agent approved by the FDA or similar regulatory agency from a country other than the US, for the treatment of fungal infections or diseases. Examples of antifungal agents include, but are not limited to A "cell" as used herein refers to a cell that performs a metabolic or other function to conserve or replicate its genomic DNA. A cell can be identified by methods well known in the art including, for example, presence of an intact membrane, staining by a particular indicator, ability to produce progeny, or, in the case of a gamete, the ability to combine with a second. gamete to produce viable offspring. The cells may include prokaryotic and eukaryotic hbh7nn / LZnZ / B / Yli cells. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells and cells derived from plants and animals, eg, mammals, insects (eg, Spodoptera), and human cells. Cells may be useful when they are naturally non-adherent or have been treated not to adhere to surfaces, eg by trypsinization. "Control" or "control experiment" is used according to its simple ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable. of the experiment. In some cases, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is a measure of the activity of a protein in the absence of a compound as described herein (including embodiments and examples). The phrase "in an amount sufficient to produce a change" means that there is a detectable difference between a level of an indicator measured before (eg, a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (eg, serum concentration) or subjective parameter (eg, a subject's feeling of well-being). "Substantially pure" indicates that a component makes up more than about 75% of the total content of the composition excluding excipients, and typically more than about 85% of the total content. More typically, "substantially pure" refers to compositions in which at least 90%, at least 95%, at least 96%, at least 97% or more of the total composition excluding excipients is the component of interest. In some cases, the component of interest will comprise greater than about 90%, greater than about 95%, or greater than about 96% of the total content of the composition excluding excipients (percentage on a weight by weight basis). "Substantially pure" indicates that the composition contains less than, up to, or no more than about 25%, 15%, 10%, 5%, or 4% known or unknown impurities. Impurities do not include excipients (eg, binders, fillers, diluents, glidants, lubricants, disintegrants, etc.). compositions In one aspect, a pharmaceutical composition is provided herein, comprising: (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral dosage or administration. In another aspect, a pharmaceutical composition is provided, comprising: (i) fine particles of the compound of Formula (I); or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral administration or dosage or in an inhalation dosage form. In some embodiments, the particles are micronized. In some embodiments, the particles have a particle size of between about 1 pm and about 750 pm. In some embodiments, at least about 10% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 20% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 30% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 40% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 50% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 60% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 70% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 80% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 90% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, at least about 95% of the particles have a particle size between about 1 pm and about 750 pm. In some embodiments, the particles are micronized. In some embodiments, at least about 10% of the particles have a particle size between about 1 pm and about 750 nm. In some embodiments, at least about 20% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 30% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 40% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 50% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 60% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 70% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 80% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 90% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, at least about 95% of the particles have a particle size between about 1 nm and about 750 nm. In some embodiments, the dosage form is a self-microemulsifying drug delivery system (SMEDDS). In some embodiments, the dosage form is a self-emulsifying drug delivery system (SEDDS). In some embodiments, the dosage form is a suspension or a solution. In some embodiments, the suspension is a colloidal suspension. In some embodiments, the dosage form is a nanosuspension. In some embodiments, the dosage form is a solid dosage form. In some embodiments, the dosage form is a spray dried dispersion dosage form. In some embodiments, the dosage form is a hot granulation dosage form. In some embodiments, the dosage form is a hot extrusion dosage form. In some embodiments, the dosage form is a microprecipitated bulk powder (MBP) dosage form. In some embodiments, the dosage form is a liquid. In some embodiments, the dosage form is a suspension, solution, syrup, or elixir. In some embodiments, the pharmaceutical composition is in a dosage form for oral dosage or administration. In some embodiments, the dosage form is a tablet or a capsule. In some embodiments, the tablet or capsule is enteric coated. In some embodiments, the dosage form is a tablet. In some embodiments, the tablet is a floating osmotic tablet. In some embodiments, the capsule is a liquid-filled hard capsule. In some embodiments, the capsule is a soft gelatin capsule. In some embodiments, the dosage form is a modified release dosage form. In some embodiments, the modified release dosage form is a delayed release dosage form, an extended release (ER) dosage form, or a directed release dosage form. In some embodiments, the ER dosage form is a sustained release (SR) dosage form or a controlled release (CR) dosage form. In some embodiments, the dosage form is an immediate release dosage form. In some embodiments, the pharmaceutical composition comprises between about 10 mg and about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 50 mg and about 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, it ranges from about 50mg to about 150mg hbh7nn / Lznz / E / Yli, about 150mg to about 250mg, about 250mg to about 350mg, about 350mg to about 450mg, about 450mg and about 550 mg, about 550 mg and about 650 mg, about 650 mg and about 750 mg, about 850 mg and about 950 mg, or about 950 mg and about 1050 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, or about 500 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg of a compound of Formula (I), or an isotopic, tautomeric variant. , pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutically acceptable excipient is a filler, disintegrant, binder, lubricant, or any combination thereof. In some embodiments, the pharmaceutically acceptable excipient is microcrystalline cellulose, pregelatinized starch, povidone, magnesium stearate, colloidal silicon dioxide, or any combination thereof. In some embodiments, the pharmaceutical composition is stable for up to 36 months at a temperature between about 2°C and about 25°C. In some embodiments, the pharmaceutical composition is stable for a period of between about 24 and about 36 months at a temperature between about 2°C and about 8°C. In some embodiments, the pharmaceutical composition comprises about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt. , solvate, or hydrate thereof. In one aspect, a pharmaceutical composition is provided herein, comprising: (i) the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for dosage or administration by intravenous (IV), intramuscular, subcutaneous or intradermal injection. In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystalline, microcrystalline, amorphous, or lyophilized. In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystal clear In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is amorphous. In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is lyophilized. In some embodiments, the dosage form is an IV dosage form. In some embodiments, the pharmaceutical composition is a solution. In some embodiments, the dosage form comprises a cosolvent. In some embodiments, the cosolvent comprises PEG200, PEG300, PEG400, PEG600, propylene glycol, ethanol, polysorbate 20, polysorbate 80, cremophor, glycerin, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), tert-butanol, or any of its combinations. In some embodiments, the dosage form further comprises an oil. In some embodiments, the oil comprises sesame oil, soybean oil, vegetable oil, poppy oil, safflower oil, or combinations thereof. In some embodiments, the dosage form further comprises a buffer solution. In some embodiments, the IV dosage form further comprises a buffer solution. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is potassium phosphate. In some embodiments, the potassium phosphate is monobasic or dibasic. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 9.0. In some embodiments of the hbh7nn / ί7Π7 / Β / ΥΙ pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 5.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 4.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 4.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 3.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 2.5 and about 3.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 5.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 4.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 4.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.0 and about 3.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 6.5. In some embodiments of the hbhznn / ιζηζ / Β / γι pharmaceutical composition, wherein the dosage form is an IV dosage form, the pH is between about 3.5 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 5.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 4.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 3.5 and about 4.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 8.5. In some hbhznn / ιζηζ / Β / γι embodiments of the pharmaceutical composition, wherein the dosage form is an IV dosage form, the pH is between about 4.0 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 5.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.0 and about 4.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and hbh7nn / ί7Π7 / Β / ΥΙ about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 4.5 and about 5.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 10.0. In some hbh7nn / LZnZ / B / Yli embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.0 and about 5.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some forms of pharmaceutical composition hbh7nn / ί7Π7 / Β / ΥΙ embodiment, wherein the dosage form is an IV dosage form, the pH is between about 5.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 5.5 and about 6.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.0 and about 6.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 10.0. In some hbh7nn / ί7Π7 / Β / ΥΙ embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 6.5 and about 7.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and hbhznn / ιζηζ / Β / γι about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.0 and about 7.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 7.5 and about 8.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.0 and about 8.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.5 and about 10.5. In some embodiments of the hbhznn / ιζηζ / Β / γι pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.5 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 8.5 and about 9.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.0 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.0 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.0 and about 9.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.5 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.5 and about 10.5. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 9.5 and about 10.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 10.0 and about 11.0. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical compositions disclosed herein, the dosage form is an IV (eg, infusion) dosage form. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is between about 10.5 and about 11.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 2.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 3.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 3.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 4.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 4.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 5.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 5.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.1. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.2. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.3. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.4. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.6. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.6. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.8. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 6.9. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.1. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.2. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.3. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.4. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.6. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.7. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.8. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 7.9.In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.1. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.2. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.3. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.4. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.6. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.7. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.8. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 8.9. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.1. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.2. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.3. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.4. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.6. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.9. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.8. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 9.9. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.0. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.1. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.2. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.3. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.4. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.5. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.6.In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.7. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.8. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 10.9. In some embodiments of the pharmaceutical composition, where the dosage form is an IV dosage form, the pH is approximately 11.0. In some embodiments, the pharmaceutical composition that is formulated for IV administration has a pH between about 2.5 and about 11.0. In some embodiments, the pharmaceutical composition that is formulated for IV administration has a pH between about 2.5 and about 5.0 or between about 2.5 and about 5.0. In some embodiments, the pharmaceutical composition that is formulated for IV administration has a pH between about 2.5 and about 4.5 or between about 7.0 and about 5.0. In some embodiments, the pH of the pharmaceutical composition that is formulated for IV administration is adjusted with hydrochloric acid and / or sodium hydroxide. In some embodiments, the pharmaceutical composition comprises between about 5 mg / mL and about 250 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 10 mg / mL and about 50 mg / mL of a compound of Formula (I), hbh7nn / ί7Π7 / Ε / ΥΙ or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 20 mg / mL and about 40 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, or about 30 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at a temperature between about -20°C and 8°C. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about -20°C. In some embodiments, the pharmaceutical composition comprises approximately 20 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at a temperature between about -20°C and 8°C when stored as a liquid. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about -20°C when stored as a liquid. In some embodiments, the pharmaceutical composition is stored in a pH insensitive container. In some embodiments, the pH insensitive container is made of glass or plastic. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at a temperature between about -20°C and 8°C when stored as a liquid in a pH-insensitive container. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about 20°C when stored as a liquid in a pH-insensitive container. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at a temperature between about -20°C and 8°C when stored as a liquid with a pH between about 2.5 and about 11.0. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about 20°C when stored as a liquid with a pH between about 2.5 and about 11.0. In some embodiments, the pharmaceutical composition is stable for up to about 24 months at temperatures between about -20°C and 8°C when stored as a liquid with a pH between about 2.5 and about 11.0 in a heat-insensitive container. pH. In some embodiments, the pharmaceutical composition is stable for a period of between about 12 and about 24 months at a temperature of about 20°C when stored as a liquid with a pH of between about 2.5 and about 11.0 in a temperature insensitive container. pH. In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions as described herein, an appropriate dosage level of a compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof generally ranges from about 1 to about 8,000 mg, from about 10 to about 2,000 mg, from about 100 to about 800 mg, from about 200 to about 600 mg, from about 1000 and about 2000 mg or about 600 to about 800 mg which can be administered in a single or multiple doses. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 , 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195 , 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800 , 825, 850, 875, 900, 925, 950, 975, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000 2,500, 3,000,4,3,000,4,500 500, 5,000, 5,500, 6,000, 6,500, 7,000, 7,500, or 8,000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg, about 2,000 mg, about 600 mg, or about 2,000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 600 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 700 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 800 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 900 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1,000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 2,000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 , 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195 , 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800 , 825, 850, 875, 900, 925, 950, 975, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000 2,500, 3,000,4,3,000,4,500 500, 5,000, 5,500, 6,000, 6,500, 7,000, 7,500, or 8,000 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 15 mg / day.In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 25 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 30 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 35 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 40 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 45 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 50 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 100 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 150 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 200 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 300 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 400 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 500 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 600 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 700 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 800 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 900 mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about. 1,000mg / day. In certain embodiments, the compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of approximately 2,000 mg / day. For oral administration, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing between about 1.0 and about 1,500 mg or about 1.0 and about 1,000 mg of a compound of Formula (I), or a isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in one embodiment, about 1, about 5, about 10, about 15, about 20, about 25, about 50, about 75, about 100, about 150 , about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, and about 1,000 mg of the compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for symptomatic titration of the patient to be treated. For oral administration, the pharmaceutical compositions provided herein can be formulated in a solid dosage form containing approximately 1.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 , 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625,650, of a compound of Formula (I), or a isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the solid dosage form is a tablet. In some embodiments, the solid dosage form is a capsule. In some embodiments, the solid dosage form is a powder. In some embodiments, the solid dosage form is a granulate. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 50 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 100 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 150 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 250 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a solid dosage form containing approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. For oral administration, the pharmaceutical compositions provided herein may be formulated as tablets containing between about 1.0 and about 1,500 mg or about 1.0 and about 1,000 mg of a compound of Formula (I), or an isotopic variant. ; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in one embodiment, about 1, about 5, about 10, about 15, about 20, about 25, about 50, about 75, about 100, about 150 , about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, and about 1,000 mg of the compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for symptomatic titration of the patient to be treated. For oral administration, the pharmaceutical compositions provided herein can be formulated as tablets containing approximately 1.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115,120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250,275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725,750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1,000, 1,100, 1,200, 1,300, 1,400, or 1,500 of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing about 50 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 100 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 150 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 250 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. For oral administration, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing between about 1.0 and about 1,500 mg or about 1.0 and about 1,000 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in one embodiment, about 1, about 5, about 10, about 15, about 20, about 25, about 50, about 75, about 100, about 150 , about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, and about 1,000 mg of the compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for symptomatic titration of the patient to be treated. For oral administration, the pharmaceutical compositions provided herein can be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 1.5, 10, 15, 20, 25, 30, 35 , 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160 , 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625 , 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1,000, 1,100, 1,200, 1,300, 1,400, or 1,500 of a compound of Formula (I) , or an isotopic vanant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 50 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 100 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 150 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein hbh7nn / ί7Π7 / Β / ΥΙ may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 250 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as a liquid (eg, a solution, suspension, or syrup) containing approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid (eg, IV) dosage form containing between about 1.0 and about 1,500 mg or about 1.0 and about 1,000 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in one embodiment, about 1, about 5, about 10, about 15, about 20, about 25, about 50, about 75, about 100, about 150 , about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, and about 1,000 mg of the compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for symptomatic titration of the patient to be treated. For oral administration, the pharmaceutical compositions provided herein can be formulated in a liquid (eg, IV) dosage form containing approximately 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 , 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170 , 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675 , 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1,000, 1,100, 1,200, 1,300, 1,400, or 1,500 of a compound of Formula (I), or a variant isotopic; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. hbh7nn / ί7Π7 / Β / ΥΙ In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 50 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 100 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 150 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 250 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated in a liquid dosage form (eg, IV) containing approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The pharmaceutical compositions can be administered on a regimen of 1 to 4 times per day, including once, twice, three times, and four times per day. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for one day and then 600 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for one day and then 800 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for one day and then 900 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for one day and then 1,000 mg once per day for the duration of treatment. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for two days and then 600 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for two days and then 800 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for two days and then 900 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for two days and then 1,000 mg once per day for the duration of treatment. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for three days and then 600 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or hbhznn / ιζηζ / Β / γι an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for three days and then 800 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic vanant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for three days and then 900 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for three days and then 1,000 mg once per day for the duration of treatment. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for four days and then 600 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for four days and then 800 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for four days and then 900 mg once per day for the duration of treatment. In other embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of approximately 1,000 mg twice per day for four days and then 1,000 mg once per day for the duration of treatment. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of about 1,000 mg once per day. In certain embodiments, a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount between hbhznn / ιζηζ / Β / γι about 40 mg to about 145 mg, about 40 to about 1,000, about 600 and about 1,000, or about 600 mg and about 2,000 mg per day until remission, recovery, or intolerable toxicity of the disease. In another aspect, a combined composition is provided, comprising: (i) the compound of Formula (I); or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one antifungal agent. In some embodiments, the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof. In some embodiments, the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole. In some embodiments, the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin. In one aspect, the invention provides a combined composition, comprising: (i) a compound of Formula (I): or an isotopic vanant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a compound of Formula (II) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the combined composition further comprises at least one pharmaceutically acceptable excipient. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are both crystalline. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 10:1. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 9:1 and about 9.99:0.01. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of between about 9.5:0.5 and about 9.9:0.1. In some embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof are present in a ratio of about 9:1, about 9.1:0.9, about 9.2:0.8, about 9.3:0.7, about 9.4:0.6, about 9.5:0.5, about 9.6:0.4, about 9.7:0.3, about 9.8:0.2, or about 9.9:0.1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is between about 100:0.01 and about 0.01:100. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 100:0.01. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 100:0.1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 100:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 100:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 80:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 70:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 60:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 50:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 40:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 30:1.In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 10:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 9:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 8:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 7:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 6:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 5:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 4:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 3:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 2:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1.5:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:1.In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:1.5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:2. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:3. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:4. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:6. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:7. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:8. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:9. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:10. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:20.In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:30. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:40. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:50. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 1:60. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a vanant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:70. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:80. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:90. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 1:100. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is approximately 0.1:100. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is about 0.01:100. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is at least about 100:0.01, 100:0.1, 100:1, 90:1, 80:1, 70:1, 60:1 , 50:1, 40:1, 30:1, 20:1, 10:1,9:1, 8:1,7:1,6:1, 5:1,4:1,3:1,2 :1, 1.5:1, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 , 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 0.1:100, or approximately 0.01:100. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, to the ratio of the compound of Formula (II), or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof, in the pharmaceutical composition is up to about 100:0.01, 100:0.1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2: 1, 1.5:1, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 1:100, 0.1:100, or approximately 0.01:100. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is between about 10:0.1 and about 0.1:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , hbh7nn / ί7Π7 / Β / ΥΙ pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 10:0.2. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.3. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.4. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 10:0.5. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.6. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.7. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 10:0.8. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 10:0.9. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 10:1. In certain embodiments, the ratio of the compound of the Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof with the ratio of the compound of Formula (II) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 9:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 8:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 7:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 6:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 5:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 4:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 3:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 2:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1.5:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:1.5.In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:2. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:2. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:3. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:4. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:5. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:6. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:7. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:8. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:9. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.9:10.In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.8:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.7:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 0.6:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.5:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.4:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.3:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.2:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.1:10. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer , pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 0.01:10. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is at least about 10:0.1, 10:0.2, 10:0.3, 10:0.4, 10:0.5, 10:0.6, 10:0.7, 10 :0.8, 10:0.9, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1 , 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 0.9:10, 0.8:10, 0.8 :10, 0.7:10, 0.6:10, 0.5:10, 0.4:10, 0.3:10, 0.2:10, or approximately 0.1:10. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is up to about 10:0.1, 10:0.2, 10:0.3, 10:0.4, 10:0.5, 10:0.6, 10:0.7, 10: 0.8, 10:0.9, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 0.9:10, 0.8:10, 0.8:10, 0.7:10, 0.6:10, 0.5:10, 0.4:10, 0.3:10, 0.2:10, or about 0.1:10. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is between about 5:1 and about 1:5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 5:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 4:1. In certain embodiments, the ratio of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 3:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 2:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1.5:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:1. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:1.5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:2. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is about 1:3. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:4.In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is approximately 1:5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is at least about 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1, 1:1.5, 1 :2, 1:3, 1:4, or approximately 1:5. In certain embodiments, the ratio of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof to the ratio of the compound of Formula (II), or an isotopic variant , tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition is up to about 5:1, 4:1, 3:1, 2:1, 1.5:1, 1:1, 1:1.5, 1: 2, 1:3, 1:4, or approximately 1:5. In some embodiments of the pharmaceutical compositions disclosed herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is substantially pure. In some embodiments of the pharmaceutical compositions disclosed herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is substantially free of hbh7nn / ί7Π7 / Β / ΥΙ impurities. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 10.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 9.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 8.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 7.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 6.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 5.0% impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 4.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 3.0% (w / w) impurity content.In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 2.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 1.0% (w / w) impurity content.In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.1% impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, "substantially free of impurities" is defined as less than about 0.05% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is substantially free of impurities. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 10.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 9.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 8.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 7.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 6.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 5.0% impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 4.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities hbh7nn / ί7Π7 / Β / ΥΙ is defined as up to about 3.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 3.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.8% (w / w) impurity content.In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 2.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.8% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.1% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 1.0% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.9% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.8% (w / w) impurity content.In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.7% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.6% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.5% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.4% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.3% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.2% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.1% impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, substantially free of impurities is defined as up to about 0.05% (w / w) impurity content. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 90% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 91% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 92% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 93% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 94% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 95% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 96% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 97% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 98% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 99% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is at least about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7% , about 99.8%, about 99.9%, or about 100% pure. hbh7nn / LZnZ / B / Yli In some embodiments of the pharmaceutical compositions disclosed herein 90% pure. In some they disclose at present 91% pure. In some they disclose at present 92% pure. In some invention, forms of invention, forms of invention, forms of disclosed in the present invention, the pharmaceutical composition is until approximately realization of the pharmaceutical compositions that the pharmaceutical composition is until approximately realization of the pharmaceutical compositions that the pharmaceutical composition is until approximately realization of the pharmaceutical compositions that the pharmaceutical composition is until approximately 93% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 94% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 95% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 96% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 97% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 98% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 99% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition is up to about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%, or about 100% pure. In some embodiments of the pharmaceutical compositions disclosed herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate an isotopic variant, tautomeric, pharmaceutically acceptable salt , solvate, or hydrate thereof; comprises less than about 10% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 9% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 8% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 7% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 6% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 5% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 4% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 3% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 2% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 1% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.9% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.8% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.7% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.6% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.5% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.4% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.3% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.2% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises less than about 0.1% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 10% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 9% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 8% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 7% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 6% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 5% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 4% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 3% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 2% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 1% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.9% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.8% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.7% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.6% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.5% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.4% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.3% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.2% of at least one impurity. In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition comprises up to about 0.1% of at least one impurity. In some embodiments, the pharmaceutical composition is substantially free of impurities. In some embodiments, the pharmaceutical composition is at least about 90% pure. In some embodiments, the pharmaceutical composition is at least about 95% pure. In some embodiments, the pharmaceutical composition is at least about 96% pure. In some embodiments, the pharmaceutical composition is at least about 97% pure. In some embodiments, the pharmaceutical composition is at least about 98% pure. In some embodiments, the pharmaceutical composition is at least about 99% pure. In some embodiments, the pharmaceutical composition is at least about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%, or about 100% pure. In some embodiments, the pharmaceutical composition comprises up to about 10% (w / w) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 10% (w / w), about 9% (w / w), about 8% (w / w), about 7% (w / w), about 6 % (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), or about 1% (w / w). p) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), or about 1% (w / w) of at least one impurity. In some embodiments, the pharmaceutical composition comprises less than about 0.9% (w / w), about 0.8% (w / w), about 0.7% (w / w), about 0.6% (w / w), about 0.5 % (w / w), about 0.4% (w / w), about 0.3% (w / w), about 0.2% (w / w), or about 0.1% (w / w) of at least one impurity. In some embodiments, the impurity is a degradant. In some embodiments, the impurity is: hbh7nn / 1 7Π7 / Ε / ΥΙΛ or any of their combinations. In some embodiments, the impurity is: In some embodiments, the pharmaceutical composition comprises up to about 4.0% (w / w) total impurities. In some embodiments, the pharmaceutical composition comprises up to about 0.5% (w / w) of any particular impurity. In some embodiments, the pharmaceutical composition comprises up to about 1.5% (w / w) of the compound: In some embodiments, the impurity in the pharmaceutical compositions disclosed in the present invention is: compound 1A The compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof of the present disclosure may be in the form of compositions suitable for delivery to a subject. In general, such compositions are "pharmaceutical compositions" comprising a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and one or more pharmaceutically or physiologically relevant diluents, carriers, or excipients. acceptable. In certain embodiments, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is present in a therapeutically acceptable amount. The pharmaceutical compositions can be used in the methods of the present invention; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject to practice the therapeutic or prophylactic methods and uses as described herein. The pharmaceutical compositions of the present invention may be formulated to be compatible with the intended method or route of administration; Exemplary routes of administration are described herein. Pharmaceutical compositions containing the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof may be in a form suitable for oral use, for example, as tablets, 100 capsules, pills, tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microspheres, or elixirs. Pharmaceutical compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents, and preservative agents with the aim of providing pharmaceutically elegant and pleasant preparations. Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture thereof. These excipients can be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphonate; granulating or disintegrating agents, eg, corn starch, or alginic acid; binding agents, eg starch, gelatin or acacia, and lubricating agents, eg magnesium stearate, stearic acid, or talc. Tablets, capsules and the like suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thus provide sustained action. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be used. They may also be coated by techniques known in the art to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene vinyl acetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide / glycolide copolymers, or copolymers. of ethylene-vinylacetate for the purpose of controlling the provision of an administered composition. For example, the oral agent may be entrapped in microcapsules prepared by coacervation techniques or by interface polymerization, using hydroxymethylcellulose or gelatin microcapsules or poly(methylmethacrylate) microcapsules, respectively, or in a colloid drug delivery system. . Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the aforementioned formulations will be apparent to those skilled in the art. 101 Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules. wherein the active ingredient is mixed with water or an oily medium, for example, peanut oil, liquid paraffin, or olive oil. The aqueous suspensions contain the active materials mixed with suitable excipients for their preparation. Said excipients may be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example, a naturally occurring phosphatide (for example, lecithin), or condensation products of an alkylene oxide with fatty acids (for example, polyoxyethylene stearate), or condensation products of ethylene oxide with long-chain aliphatic alcohols (for example, for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (for example, polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (eg polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives. Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, eg beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those described above, and flavoring agents may be added to provide a palatable oral preparation. Dispersible powders and granules suitable for the preparation of an aqueous suspension by the addition of water provide the active ingredient mixed with a dispersing or wetting agent, and optionally one or more suspending agents and / or preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein. The pharmaceutical compositions of the present invention may also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, eg olive oil or peanut oil, or a mineral oil, eg liquid paraffin, or a mixture of these. Suitable emulsifying agents can be gums of natural origin, hbh7nn / LZnZ / B / Yli 102 for example, gum acacia or gum tragacanth; naturally occurring phosphatides, eg, soybean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, eg sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. Pharmaceutical compositions typically comprise a therapeutically effective amount of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and one or more pharmaceutically and physiologically acceptable formulation agents. Pharmaceutically acceptable and physiologically acceptable diluents, vehicles or excipients include, but are not limited to, antioxidants (for example, ascorbic acid and sodium bisulfate), preservatives (for example, benzyl alcohol, methyl parabens, ethyl or n-propyl, phydroxybenzoate ), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, thickening agents, detergents, buffering agents, carriers, diluents, and / or adjuvants. For example, a suitable carrier may be physiological saline or citrate-buffered saline, possibly supplemented with other materials customary in pharmaceutical compositions for parenteral administration. Other exemplary vehicles are neutral buffered saline or saline mixed with serum albumin. Those of skill in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. By way of example, the buffering components can be water-soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof (for example, monobasic potassium phosphate, dibasic potassium phosphate, etc.). Acceptable buffering agents include, for example, a Tris buffer; N-(2Hydrox¡et¡l)piperaz¡na-N'-(2-ethanesulfonic acid) (HEPES); 2-(N-Morpholino)ethanesulfonic acid (MES); 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES); 3-(NMorfolino)propanesulfonic acid (MOPS); and N-tr¡s[Hydrox¡methyl]methyl-3-am¡nopropanesulfón¡co acid (TAPS), monobasic potassium phosphate, and dibasic potassium phosphate. After a pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored in a ready-to-use form, a lyophilized form that requires reconstitution before use, a liquid form that requires dilution before use, or other acceptable form. In some embodiments, the hbhznn / ιζηζ / Β / γι 103 pharmaceutical composition is provided in a single-use container (for example, a single-use vial, ampoule, syringe, or autoinjector (similar to, for example, an EpiPen®)), while for other embodiments a single-use container is provided. multi-use container (for example, a multi-use vial). Formulations can also include vehicles to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including liposomes, hydrogels, prodrugs, and microencapsulated delivery systems. For example, a time delay material such as glyceryl monostearate or glyceryl stearate may be used alone, or in combination with a wax. Any drug delivery apparatus can be used to deliver a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; including implants (eg, implantable pumps) and catheter systems, pumps, and slow injection devices, all of which are well known to those of skill in the art. Depot injections, which are generally administered subcutaneously or intramuscularly, can also be used to deliver the compound (for example, a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof) which is disclosed in the present invention for a defined period of time. Depot injections usually have a solid or oil base and generally comprise at least one of the formulation components described herein. One of ordinary skill in the art is familiar with the possible formulations and uses of depot injections. The pharmaceutical compositions may be in the form of a sterile aqueous or oily injectable suspension. This suspension can be formulated in accordance with the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic diluent or solvent acceptable for the parenteral route, for example, as a solution in 1,3-butanediol. Acceptable diluents, solvents, and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor® EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium; any bland fixed oil may be used for this purpose, including hbhznn / ιζηζ / Β / γι 104 synthetic mono or diglycerides. Furthermore, fatty acids, such as oleic acid, can be used for the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by the inclusion of an agent that delays absorption (eg, aluminum monostearate or gelatin). The present invention contemplates the administration of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the form of suppositories for rectal administration. Suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at rectal temperatures and therefore melts in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols. The compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof may be in the form of any other suitable pharmaceutical composition (eg, sprays for nasal use or inhalation) presently known or developed in the future. Methods of Use In one aspect, the invention provides a method of treating and / or preventing an infection or fungal disease, which comprises administering to a subject in need thereof a therapeutically effective amount of any of the pharmaceutical compositions or combination compositions as described herein. . In one aspect, the invention provides a method of treating and / or preventing a fungal infection or disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, comprising: (i) the compound of the Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, and the pharmaceutical composition is in a dosage form for oral dosage or administration. In another aspect, the invention provides a method of treating and / or preventing a fungal infection or disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, comprising: (i) fine particles of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (¡i) at least one excipient hbh7nn / ί7Π7 / Β / ΥΙ 105 pharmaceutically acceptable, wherein the pharmaceutical composition is in a dosage form for oral dosage or administration or in an inhalation dosage form. In some embodiments of the methods of the invention, the dosage form is a self-microemulsifying drug delivery system (SMEDDS). In some embodiments of the methods of the invention, the dosage form is a self-emulsifying drug delivery system (SEDDS). In some embodiments of the methods of the invention, the dosage form is a suspension or a solution. In some embodiments of the methods of the invention, the dosage form is a nanosuspension. In some embodiments of the methods of the invention, the dosage form is a solid dosage form. In some embodiments of the methods of the invention, the dosage form is a spray dried dispersion dosage form. In some embodiments of the methods of the invention, the dosage form is a hot granulation dosage form. In some embodiments of the methods of the invention, the dosage form is a hot extrusion dosage form. In some embodiments of the methods of the invention, the dosage form is a microprecipitated bulk powder (MBP) dosage form. In some embodiments of the methods of the invention, the dosage form is a liquid. In some embodiments of the methods of the invention, the dosage form is a suspension, solution, syrup, or elixir. In some embodiments of the methods of the invention, the pharmaceutical composition is in a dosage form for oral dosage or administration. In some embodiments of the methods as described herein, the dosage form is a tablet or capsule. In some embodiments of the methods as described herein, the tablet or capsule is enteric coated. In some embodiments of the methods as described herein, the dosage form is a tablet. In some embodiments of the methods as described herein, the tablet is a floating osmotic tablet. In some embodiments of the methods as described herein, the capsule is a liquid-filled hard capsule. In some embodiments of the methods as described herein, the capsule is a soft gelatin capsule. In some embodiments of the methods as described herein, the dosage form is a modified release dosage form. In some hbh7nn / ί7Π7 / Β / ΥΙ In embodiments of the methods as described herein, the modified release dosage form is a delayed release dosage form, an extended release (ER) dosage form, or a directed release dosage form. In some embodiments of the methods as described herein, the ER dosage form is a sustained release (SR) dosage form or a controlled release (CR) dosage form. In some embodiments of the methods as described herein, the dosage form is an immediate release dosage form. In one aspect, the invention provides a method of treating and / or preventing a fungal infection or disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, comprising: (i) the compound of the Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for dosage or administration by intravenous (IV), intramuscular, subcutaneous or intradermal injection. In some embodiments of the methods as described herein, the form is an IV dosage form. hbh7nn / LZnZ / B / Yli In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of approximately 20 minutes, about 30 minutes, about 60 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, approximately 12 hours, approximately 18 hours, or approximately 24 hours by IV infusion. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of up to about 1 hour by IV infusion. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of up to about 2 hours by IV infusion. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of up to about 3 hours by IV infusion. 107 In another aspect, a method of treating a fungal infection or disease is provided, comprising administering to a subject in need thereof a therapeutically effective amount of a combined composition, comprising: (i) the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one antifungal agent. In one aspect, the invention provides a method of treating and / or preventing a fungal infection or disease, comprising administering to a subject in need thereof a therapeutically effective amount of a combined composition, comprising: hbh7nn / ί7Π7 / Β / ΥΙ (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a compound of Formula (II): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods as described herein, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystalline, microcrystalline, amorphous, or lyophilized. In some embodiments of the methods as described herein, the compound of Formula (I) or an isotopic vanant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is crystal clear In some embodiments of the methods as described herein, the compound of Formula (I) or an isotopic vanant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is amorphous. in some ways 108 of carrying out the methods as described herein, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; it is lyophilized. In some embodiments of the methods of the invention, the subject is administered about 10 mg and about 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, between about 10 mg and about 2,400 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered to the subject. . In some embodiments of the methods of the invention, the subject is administered about 10 mg, about 30 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,200 mg, about 1,500 mg, about 1,800 mg, about 2,000 mg, about 2,100 mg, about 2,400 mg, about 2,500 mg, about 3,000 mg, about 4,000 mg, about 5,000 mg, about 6,000 mg, about 7,000 mg, or about 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered about 40 mg, about 50 mg, about 100 mg, about 200 mg, about 250 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, or about 900 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered about 600 mg, about 700 mg, about 800 mg, about 900 mg, 1,000 mg, about 2,000 mg, or about 3,000 mg of the compound of Formula (I ), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. 109 In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject daily. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject once per day, twice per day, three times per day, or four times per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject once per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject twice per day. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject for a period of up to about 12 weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of at least one week. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of at least two weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject for a period of up to about 2 weeks. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of one week, two weeks, 6 weeks, 12 weeks, 24 weeks, 48 ​​weeks, or 52 weeks. In some embodiments of the methods of the invention, between about 10 mg and about 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate is administered to the subject. of the same. In some embodiments of the methods of the hbh7nn / IZéZ / B / Yli invention, the subject is administered approximately 10 mg, approximately 20 mg, about 30 mg, about 40 mg, about 50 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, or about 2,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of approximately 20 minutes, 110 about 30 minutes, about 60 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 12 hours, approximately 18 hours, or approximately 24 hours by IV infusion. In some embodiments of the methods of the invention, the pharmaceutical composition is administered to the subject over a period of up to about 3 hours by IV infusion. In some embodiments of the methods of the invention, the subject is administered a loading dose followed by a maintenance dose. In some embodiments of the methods of the invention, the loading dose comprises between about 1,000 mg and about 8,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate. of the same. In some embodiments of the methods of the invention, the maintenance dose comprises between about 600 mg and about 2,400 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate. of the same. In some embodiments of the methods of the invention, the loading dose is between about 1,000 mg and about 2,000 mg. In some embodiments of the methods of the invention, the loading dose is administered over a period of between about 2 and about 3 hours by IV infusion. In some embodiments of the methods of the invention, the loading dose is administered twice during the first day of treatment. In some embodiments of the methods of the invention, the second loading dose is administered approximately 9 hours after the first loading dose. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1,000 mg of a compound of Formula (I), or a variant. isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the maintenance dose comprises about 800 mg or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the same. In some embodiments of the methods of the invention, the maintenance dose comprises 111 about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the itself and is administered orally. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate of the It is administered over a period of approximately 1 hour and approximately 3 hours by IV infusion. In some embodiments of the methods of the invention, the method of any of embodiments 157-164, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomeric, pharmaceutically acceptable salt is administered. , solvate, or hydrate thereof over a period of about 3 hours by IV infusion. In some embodiments of the methods of the invention, the maintenance dose is administered once per day. In some embodiments of the methods of the invention, the maintenance dose is administered once per day beginning on the second day of treatment. In some embodiments of the methods of the invention, about 600 mg or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered throughout over a period of approximately 3 hours by IV infusion starting on the second, third, or fourth day of treatment. In some embodiments of the methods of the invention, about 800 mg or about 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered via the oral from the second third or fourth day of treatment. In some embodiments of the methods of the invention, the maintenance dose comprises about 600 mg or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomeric, pharmaceutically 112 acceptable, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the subject is administered approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of about 1 hour and about 3 hours by IV infusion and / or about 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and administered orally . In some embodiments of the methods of the invention, the maintenance dose is administered once per day. In some embodiments of the methods of the invention, the maintenance dose is administered once per day beginning on the second day of treatment. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of approximately 3 hours by IV infusion. In some embodiments of the methods of the invention, approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered over a period of time. of approximately 3 hours by IV infusion from the second day of treatment. In some embodiments of the methods of the invention, approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered orally from the fourth day of treatment. In some embodiments of the methods of the invention, the fungal infection is caused by an invasive fungus. In some embodiments of the methods of the invention, the method further comprises administering to the subject at least one antifungal agent in combination with the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomeric, pharmaceutically acceptable, solvate, or hydrate thereof. In some embodiments of the methods of the invention, the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or their 113 combinations. In some embodiments of the methods of the invention, the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole. In some embodiments of the methods of the invention, the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin, or combinations thereof. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously, approximately simultaneously, or sequentially, in any order. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously or approximately simultaneously. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered sequentially. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered before the antifungal agent. In some embodiments of the methods of the invention, the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered after the antifungal agent. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a fungus Aspergillus fumigatus, Blastomyces, Ajellomyces, Candida, Coccidioides, Cryptococcus, Histoplasm, Rhizopus Muco, Cunninghamell, Apophysomyces, Absidi, Saksenaea, Entomophthora, Conidiobolus, Basidiobolus, Sporothrix, Pneumocystis, Talaromyces, Asclepias, Fusarium, Scedosporium or by a fungus of the order Mucorales, or any of their combinations. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a Cryptococcus, Aspergillus, Candida, Fusarium, Scedosporium fungus, or by a fungus of the order Mucorales, or any combination thereof. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a fungus Aspergillus fumigatus, Aspergillus flavus, Blastomyces dermatitidis, Ajellomyces dermatitidi, Candida albican, Candida glabrata, Candida rugosa, Candida auris, Coccidioides 114 immitis, Coccidioides posadasii, Cryptococcus neoformans, Cryptococcus gattii, Histoplasma capsulatum, Rhizopus stolonifer, Rhizopus arrhizus, Mucor indicus, Cunninghamella bertholletiae, Apophysomyces elegans, Absidia spp., Saksenaea spp., Rhizomucor pusillus, Entomocor pusillus spp., Basidious contomophthora spp., Sporidiousbolophthora spp. chenckii , Pneumocystis jirovecii, Talaromyces marneffei, Asclepias albicans, Fusarium solani, Scedosporium apiospermum, Rhizomucor pusillus, or any of their combinations. In some embodiments of the methods of the invention, the infection or fungal disease is caused by a Cryptococcus fungus or a Candida fungus. In some embodiments of the methods of the invention, the infection or fungal disease is caused by Cryptococcus neoformans, Cryptococcus gattii, or Candida auris. In some embodiments of the methods of the invention, the fungal infection or disease is resistant to the azole and / or resistant to the echinocandin. In some embodiments of the methods of the invention, the subject is immunocompromised. In some embodiments of the methods of the invention, the subject is infected with HIV / AIDS or has cancer. In some embodiments of the methods of the invention, the subject has cancer. In some embodiments of the methods of the invention, the cancer is acute myeloid leukemia (AML). In some embodiments of the methods of the invention, the subject is neutropenic. In some embodiments of the methods of the invention, the subject is or has been undergoing chemotherapy treatment for cancer. In some embodiments of the methods of the invention, the subject is or has been under corticosteroid treatment. In some embodiments of the methods of the invention, the subject is or has been under treatment with TNF inhibitors. In some embodiments of the methods of the invention, the subject is the recipient of a transplant. In some embodiments of the methods as described herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered to the subject in combination with posaconazole. In some embodiments of the methods as described herein, the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered to the subject for the prevention of a infection or fungal disease. In some embodiments of the methods as described herein, the subject is administered the compound of Formula (I), or an isotopic variant, hbh7nn / ί7Π7 / Β / ΥΙ 115 tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof for the treatment of an existing fungal infection or disease. In some embodiments of the methods of the invention, the infection or fungal disease is in the subject's bloodstream. In some embodiments of the methods of the invention, the subject has a reduced fungal colony count in the lungs after administration of the pharmaceutical composition. In some embodiments of the methods of the invention, the plasma concentration vs. time curve of the compound of Formula (I) in the subject has a tmax of less than between about 30 minutes and about 180 minutes. In some embodiments of the methods of the invention, the subject has a maximum plasma concentration (Cmax) of between about 12,000 ng / mL and about 25,000 ng / mL of the compound of Formula (I Dosage In some embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof pharmaceutical compositions as described herein are supplied at the maximum tolerated dose (MTD) for the compound of Formula (I). In other embodiments, the amount of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the pharmaceutical composition that is administered is between about 10% and about 90% of the maximum tolerated dose (MTD) is between about 25% and about 75% of the MTD, or about 50% of the MTD. In some other embodiments, the amount of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof in the administered pharmaceutical compositions is between about 5%, 10%, 15%. %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or greater, or any range derivable therefrom, of the MTD for the compound of Formula (I). In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions as described herein (eg, an infection or fungal disease), an appropriate dosage level of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof generally ranges from about 1 to 8,000 mg, from about 10 to 8,000 mg, from about 10 to 2,000 mg, from 116 about 1 to about 1,000 mg, about 25 to about 1,000 mg, about 25 to about 800 mg, about 25 to about 600 mg, about 50 to about 600 mg, about 50 to about 300 mg, about 50 to about 150 mg, about 150 to about 250 mg, about 250 to about 350 mg, about 350 to about 450 mg, about 450 to about 550 mg, about 550 to about 650 mg, about 650 and about 750 mg, between about 750 and about 850 mg, which can be administered in a single or multiple doses. In certain embodiments, the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200 , about 205, about 210, about 215, about 220, about 225, about 230, about 240, about 250, about 260, about 270, about 275, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg , about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, 117 about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, 710 mg, approximately 720 mg, approximately 730 mg, approximately 740 mg, approximately 750 mg, approximately 760 mg, approximately 770 mg, approximately 780 mg, approximately 790 mg, approximately 800 mg, approximately 810 mg, approximately 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg , about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1,000, about 1,100, about 1,200, about 1,300, about 1,400, about 1,500, about 1,600, about 1,700, about 1,800, about 1,900, about 2,000, about 2,100, about 2,200, about 2,300, about 2,400, about 2,500, about 2,600, about 2,700, about 2,800, about 3,000, about 4,000, about 5,000, about 6,000, about 7,000, about 8,000 mg, or any range derived therefrom . In certain embodiments, the compound of Formula (I) or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof are administered to the subject in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 118 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 240, about 250, about 260, about 270, about 275, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg , about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, 910 mg, about 920 about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1,000, about 1,100, about 1,200, about 1,300, about 1,400, about 1,500, about 1,600 , about 1,700, about 1,800, about 1,900, about 2,000, about 2,100, about 2,200, about 2,300, about 2,400, about 2,500, about 2,600, about 2,700, about 2,800, about 3,000, about 4,000, about 5,000, about 6,000 7,000, approximately 8,000 mg. 119 In certain embodiments, the compound of Formula (I) or a variant isotopic, tautomeric, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 240, about 250, about 260, about 270, about 275, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, 710 mg, about 720 mg , approximately 730 mg, approximately 740 mg, approximately 750 mg, approximately 760 mg, approximately 770 mg, approximately 780 mg, approximately 790 mg, approximately 800 mg, approximately 810 mg, approximately 820 mg, approximately 830 mg, approximately 840 mg, approximately 850mg, about 860mg, about 870mg, 120 about 880 mg, about 890 mg, about 900 mg, 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1,000 , about 1,100, about 1,200, about 1,300, about 1,400, about 1,500, about 1,600, about 1,700, about 1,800, about 1,900, about 2,000, about 2,100, about 2,200, about 2,300, about 2,400, about 2,500, about 2,600 2,700, about 2,800, about 3,000, about 4,000, about 5,000, about 6,000, about 7,000, about 8,000 mg / day. For oral administration, the pharmaceutical compositions provided herein may be formulated as tablets or capsules containing between about 1 and about 2,000 mg, about 10 and about 2,000 mg, between about 1 and about 1,000 mg, about 25 and about 1,000 mg. about 25 and about 800 mg, about 25 and about 600 mg, about 50 and about 600 mg, about 50 and about 300 mg, about 50 and about 150 mg, about 150 and about 250 mg, about 250 mg and about 350 mg, about 350 and about 450 mg, about 450 and about 550 mg, about 550 and about 650 mg, about 650 and about 750 mg, about 750 and about 850 mg; in one embodiment, 1 mg, approximately 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, approximately 220 mg, 121 approximately 230 mg, approximately 240 mg approximately 250 mg, approximately 260 mg, approximately 270 mg approximately 280 mg, approximately 290 mg, approximately 300 mg approximately 310 mg, approximately 320 mg, approximately 330 mg approximately 340 mg, approximately 350 mg, approximately 360 mg approximately 370 mg, approximately 380 mg, approximately 390 mg approximately 400 mg, 410 mg, approximately 420 mg, approximately 430 mg approximately 440 mg, approximately 450 mg, approximately 460 mg approximately 470 mg, approximately 480 mg, approximately 490 mg approximately 500 mg, approximately 510 mg, approximately 520 mg approximately 530 mg, approximately 540 mg, approximately 550 mg approximately 560 mg, approximately 570 mg, approximately 580 mg approximately 590 mg, approximately 600 mg, approximately 610 mg approximately 620 mg , approximately 630 mg, approximately 640 mg approximately 650 mg, approximately 660 mg, approximately 670 mg approximately 680 mg, approximately 690 mg, approximately 700 mg, 710 mg approximately 720 mg, approximately 730 mg, approximately 740 mg approximately 750 mg, approximately 760 mg, approximately 770 mg approximately 780 mg, approximately 790 mg, approximately 800 mg approximately 810 mg, approximately 820 mg, approximately 830 mg approximately 840 mg, approximately 850 mg, approximately 860 mg approximately 870 mg, approximately 880 mg, approximately 890 mg approximately 900 mg, 910 mg, approximately 920 mg, approximately 930 mg approximately 940 mg, approximately 950 mg, approximately 960 mg approximately 970 mg, approximately 980 mg, approximately 990 mg about 1,000, or about 2,000 mg of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof for symptomatic titration of the patient to be treated. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets or capsules containing about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, or about 800 mg of a 122 compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for oral administration to contain approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for oral administration to contain approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for oral administration to contain approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for oral administration to contain approximately 500 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as tablets containing approximately 500 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The pharmaceutical compositions provided herein may be formulated for administration by injection or IV infusion and contain between about 1 and 123 2,000 mg, about 10 to about 2,000 mg, about 1 to about 1,000 mg, about 25 to about 1,000 mg, about 25 to about 800 mg, about 25 to about 600 mg, about 50 to about 600 mg, about 50 to about 300 about 50 and about 150 mg, about 150 and about 250 mg, about 250 and about 350 mg, about 350 and about 450 mg, about 450 and about 550 mg, about 550 and about 650 mg, about 650 and about 750 mg, about 750 and about 850 mg, about 850 and about 950 mg, about 950 and about 1050 mg; in one embodiment, 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg , about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620mg, 124 about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg , about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1,000, or about 2,000 mg of the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, symptomatic of the dosage of the patient to be treated. or hydrate thereof for adjustment In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by injection or IV infusion and contain about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 950 mg, or about 1,000 mg of a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by injection or IV infusion containing approximately 200 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 300 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by injection or IV infusion containing approximately 125 400 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 500 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 600 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 700 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 800 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 900 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated for administration by IV injection or infusion containing approximately 1,000 mg of a compound of Formula (I), or an isotopic variant; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the pharmaceutical compositions provided herein may be formulated as an IV injection or infusion containing between about 5 mg / mL and about 250 mg / mL, between about 10 mg / mL and about 150 mg / mL, between approximately 10 mg / mL and approximately 100 mg / mL, between approximately 10 mg / mL and approximately 50 mg / mL, between approximately 10 mg / mL and approximately 40 mg / mL, or between approximately 10 mg / mL and approximately 30 mg / mL; in one embodiment, 1 mg / mL, approximately 5 mg / mL, approximately 10 mg / mL, approximately 15 mg / mL, approximately 20 mg / mL, approximately 25 mg / mL, approximately 30 mg / mL, about 35 about 50 about 65 about 80 12 6 mg / mL, about 40 mg / mL, about 45 mg / mL, mg / mL, about 55 mg / mL, about 60 mg / mL, mg / mL, about 70 mg / mL, approximately 75 mg / mL, mg / mL, approximately 85 mg / mL, approximately 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 135 mg / mL, approximately 140 mg / mL, approximately 145 mg / mL, approximately 150 mg / mL, approximately 155 mg / mL, approximately 160 mg / mL, approximately 170 mg / mL, approximately 180 mg / mL, approximately 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, of a compound of Formula (I), or a isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises between about 20 mg / mL and about 40 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, or about 30 mg / mL of a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, the pharmaceutical composition comprises approximately 20 mg / mL of a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. The daily dose as described herein may be administered once a day or multiple times a day in the form of sub-doses administered b.i.d., t.i.d., q.i.d., or the like when the amount of sub-dose equals the daily dose. The pharmaceutical compositions can be administered on a regimen of 1 to 4 times per day, including once, twice, three times, and four times per day. In some embodiments, the pharmaceutical compositions are administered once per day. In some embodiments, the pharmaceutical compositions are administered twice per day. In some embodiments, the pharmaceutical compositions are administered three times per day. In some embodiments, the pharmaceutical compositions are administered four or more times per day. In some embodiments, a loading dose, and then a maintenance dose, of a compound is administered. 127 of Formula (I), or an isotopic variant, tautomer, salt are provided as a pharmaceutically acceptable tablet, solvate, or hydrate thereof. In some embodiments, the pharmaceutical compositions herein are administered as a tablet. In some embodiments, the pharmaceutical compositions of the present invention are administered as a capsule. In some embodiments, the pharmaceutical compositions of the present invention are administered as an injection. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV injection or infusion. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 10 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 15 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 20 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 30 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 45 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately one hour. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately 90 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately two hours. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of approximately three hours. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of up to about three hours. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of at least three hours. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of at least 30 minutes. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of at least 2 hours. In some forms hbh7nn / ί7Π7 / Β / ΥΙ 128 of embodiment, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of up to 2 hours. In some embodiments, the pharmaceutical compositions of the present invention are administered as an IV infusion over a period of up to 30 minutes. In some embodiments, a loading dose is administered followed by a maintenance dose of the pharmaceutical compositions of the present invention. In some embodiments, the loading dose and the maintenance dose are both administered by IV infusion. In some embodiments, the loading dose and the maintenance dose are both administered orally (PO). In some embodiments, the loading dose is administered by IV infusion and the maintenance dose is administered orally (PO). In some embodiments, a loading dose comprising approximately 2,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered by IV infusion. In some embodiments, a loading dose comprising approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered twice per day (BID ) by IV infusion. In some embodiments, a loading dose comprising approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered BID by IV infusion on the first treatment day. In some embodiments, a loading dose comprising approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered BID by IV infusion on the first treatment day only. In some embodiments, a loading dose comprising approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof is administered BID by IV infusion in 1 hour or 2 hours. In some embodiments, QD is administered a maintenance dose comprising approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof by IV infusion. In some embodiments, QD is administered a maintenance dose comprising approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof by IV infusion from of the second day of treatment. In some embodiments, a maintenance dose comprising approximately 600 mg of the pharmaceutical compositions of the present invention is administered QD by IV infusion over 1 hour or 2 hours. In hbh7nn / ί7Π7 / Β / ΥΙ In some embodiments, QD PO is administered a maintenance dose comprising approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, BID is administered by IV infusion 1,000 mg (loading dose) followed by QD by IV infusion 600 mg (maintenance dose) of a compound of Formula (I), or an isotopic variant, tautomer, salt pharmaceutically acceptable, solvate, or hydrate thereof. In some embodiments, BID is administered by IV infusion over 2 or 3 hours with 1,000 mg (loading dose) followed by QD by IV infusion over 1, 2 or 3 hours with 600 mg (maintenance dose) of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, BID is administered by IV infusion over 3 hours 1,000 mg (loading dose) followed by QD by IV infusion over 3 hours 600 mg (maintenance dose) of a compound of Formula (I), or a isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, 1,000 mg (loading dose) is administered BID by IV infusion over 3 hours followed by PO QD 800 mg (maintenance dose) of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. In some embodiments, a 1,000 mg IV loading dose is administered BID by IV infusion over 2 or 3 hours, with the second dose being administered between about 9 and about 12 hours after the first dose. In some embodiments, the pharmaceutical compositions of the present invention are administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, approximately 28 days, approximately 29 days, or approximately 30 days. In some embodiments, the pharmaceutical compositions of the present invention are administered daily, every other day, every other day 3 times a week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 3 days, every 4 days, 130 every 5 days, every 6 days, weekly, every 2 weeks, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months. In some instances, the method for the administration of multiple compounds (for example, a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and an antifungal agent) comprises the administration of compounds within 48 hours or less of each other. In some embodiments, administration occurs within 24 hours, 16 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours. , 1 hour, 30 minutes, 20 minutes, 15 minutes, or 10 minutes. In some instances, the compounds are administered simultaneously. An example of simultaneous administration is injection of one compound immediately before, after, or during oral administration of the second compound, where immediately means less than about 5 minutes later. In some embodiments of the pharmaceutical compositions described herein, a second dose is administered approximately 10 minutes after the first dose, a second dose is administered approximately 15 minutes after the first dose, a second dose is administered approximately 20 minutes after the first. dose, a second dose is given approximately 30 minutes after the first dose, a second dose is given approximately 40 minutes after the first dose, a second dose is given approximately 45 minutes after the first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, first dose, a second dose is given about 1 a second dose is given a second dose is given a second dose is given a second a second is administered a second is administered a second is administered a second is administered a second is administered a second is administered a second is administered a second dose is administered approximately 2 doses approximately 3 doses approximately 4 doses approximately 5 doses approximately 6 doses approximately 7 doses about 8 doses about 9 doses about 10 doses about 11 doses about 12 doses about 13 hours after hours after hours after hours after hours after hours after hours after hours after hours after hours after hours after hours after to to to to to to to to to to to to to 131 first dose, a second dose is given approximately 14 hours after the first dose, a second dose is given approximately 15 hours after the first dose, a second dose is given approximately 16 hours after the first dose, a second dose is given approximately 17 hours after the first dose, a second dose is administered approximately 18 hours after the first dose, a second dose is administered approximately 19 hours after the first dose, a second dose is administered approximately 20 hours after the first dose , a second dose is administered approximately 21 hours after the first dose, a second dose is administered approximately 22 hours after the first dose, a second dose is administered approximately 23 hours after the first dose, or a second dose is given approximately 24 hours after a first dose. In some embodiments of the pharmaceutical compositions described herein, the second dose is administered approximately 10 minutes, approximately 15 minutes, approximately 20 minutes, approximately 30 minutes, approximately 40 minutes, approximately 45 minutes, approximately 1, approximately 2, approximately 3 , about 4, about5, about 6, about 7, about 8, about9, about 10, about 11, about 12, about13, about 14, about 15, about 16, about17, about 18, about 19, about 20, about21, about 22, about 23, about 22, or about 48 hours after completion of administration of the first dose by IV infusion. In some embodiments of the pharmaceutical compositions, the second dose is administered approximately 10 minutes, approximately 15 minutes, approximately 20 minutes, approximately 30 minutes, approximately 40 minutes, approximately 45 minutes, approximately 1, approximately 2, approximately 3, approximately 4 , about 5, about 6, about 7, about8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about16, about 17, about 18, about 19, about20, about 21, about 22, about 23, about 22, or about 48 after the start of administration of the first dose by IV infusion. In some embodiments, the pharmaceutical compositions described herein are administered in combination with an antifungal agent. In some forms of In one embodiment, the pharmaceutical compositions described herein are administered prior to the antifungal agent. In some embodiments, the pharmaceutical compositions described herein are administered after the antifungal agent. In some embodiments, the pharmaceutical compositions described herein are administered simultaneously with the antifungal agent. In some embodiments, the pharmaceutical compositions described herein and the antifungal agent are both administered by IV infusion. In some embodiments, the pharmaceutical compositions described herein and the antifungal agent are both administered orally. In some embodiments, the pharmaceutical compositions described herein are administered orally and the antifungal agent is administered by IV infusion. In some embodiments, the pharmaceutical compositions described herein are administered by IV infusion and the antifungal agent is administered orally. In some embodiments, the pharmaceutical compositions described herein and the antifungal agent are administered orally. In some embodiments, the pharmaceutical compositions described herein and the antifungal agent are administered by IV infusion. In some embodiments, the pharmaceutical formulations of the present invention are formulated to achieve, after a minimal period of time post-administration, a maximum plasma concentration (Cmax) of between about 12,000 ng / mL and about 25,000 ng / mL. mL (ie, approximately 12 pg / mL and approximately 25 pg / mL). In some embodiments, the formulations hbh7nn / ί7Π7 / Ε / ΥΙ The pharmaceuticals of the present invention are formulated to achieve, after a minimal period of time post-administration, a Cmax of between about 12 pg / mL and about 13 pg / mL, 12 pg / mL. and approximately 14 pg / mL, 12 pg / mL and approximately 15 pg / mL, 12 pg / mL and approximately 16 pg / mL, 12 pg / mL and approximately 17 pg / mL, 12 pg / mL and approximately 18 pg / mL , 12 pg / mL and approximately 19 pg / mL, 12 pg / mL and approximately 20 pg / mL, 12 pg / mL and approximately 21 pg / mL, 12 pg / mL and approximately 22 pg / mL, 12 pg / mL and about 23 pg / mL, 12 pg / mL and about 24 pg / mL, 13 pg / mL and about 14 pg / mL, 13 pg / mL and about 15 pg / mL, 13 pg / mL and about 16 pg / mL, 13 pg / mL and approximately 17 pg / mL, 13 pg / mL and approximately 18 pg / mL, 13 pg / mL and approximately 19 pg / mL, 13 pg / mL and approximately 20 pg / mL, 13 pg / mL and approximately 21 pg / mL, 13 pg / mL and approximately 22 pg / mL, 13 pg / mL and approximately 23 pg / mL, 13 pg / mL and approximately 24 pg / mL, 13 pg / mL and approximately 25 pg / mL, 14 pg / mL and approximately 15 pg / mL, 14 pg / mL and approximately 16 pg / mL, 14 pg / mL and 133 approximately 17 pg / mL, 14 pg / mL, and approximately 18 pg / mL, 14 pg / mL approximately 19 pg / mL, 14 pg / mL, and approximately 20 pg / mL, 14 pg / mL approximately 21 pg / mL, 14 pg / mL and approximately 22 pg / mL, 14 pg / mL approximately 23 pg / mL, 14 pg / mL and approximately 24 pg / mL, 14 pg / mL approximately 25 pg / mL, 15 pg / mL and ap...

Claims

1. A pharmaceutical composition comprising: (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral dosing or administration.

2. A pharmaceutical composition comprising: (i) fine particles of a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for oral dosage or administration or in an inhalation dosage form.

3. The pharmaceutical composition of claim 1 or 2, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is crystalline, microcrystalline, amorphous, or lyophilized.

4. The pharmaceutical composition of claim 3, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is crystalline.

5. The pharmaceutical composition of claim 3, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is amorphous.

6. The pharmaceutical composition of claim 3, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is lyophilized.

7. The pharmaceutical composition of any of claims 2-6, wherein the particles are micronized.

8. The pharmaceutical composition of claim 7, wherein the particles have a particle size of between approximately 1 μm and approximately 750 pm.

9. The pharmaceutical composition of claim 7 or 8, wherein at least approximately 10% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

10. The pharmaceutical composition of any of claims 7-9, wherein at least approximately 20% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

11. The pharmaceutical composition of any of claims 7-10, wherein at least approximately 30% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

12. The pharmaceutical composition of any of claims 7-11, wherein at least approximately 40% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

13. The pharmaceutical composition of any of claims 7-12, wherein at least approximately 50% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

14. The pharmaceutical composition of any of claims 7-13, wherein at least approximately 60% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

15. The pharmaceutical composition of any of claims 7-14, wherein at least approximately 70% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

16. The pharmaceutical composition of any of claims 7-15, wherein at least approximately 80% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

17. The pharmaceutical composition of any of claims 7-16, wherein at least approximately 90% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

18. The pharmaceutical composition of any of claims 7-17, wherein at least approximately 95% of the particles have a particle size of between approximately 1 pm and approximately 750 pm.

19. The pharmaceutical composition of any of claims 2-6, wherein the particles are micronized.

20. The pharmaceutical composition of claim 19, wherein the particles have a particle size of between approximately 1 nm and approximately 750 nm.

21. The pharmaceutical composition of claim 19 or 20, wherein at least approximately 10% of the particles have a particle size of between 1 nm and approximately 750 nm.

22. The pharmaceutical composition of any of claims 19-21, wherein at least approximately 20% of the particles have a particle size of between 1 nm and approximately 750 nm.

23. The pharmaceutical composition of any of claims 19-22, wherein at least approximately 30% of the particles have a particle size of between 1 nm and approximately 750 nm.

24. The pharmaceutical composition of any of claims 19-23, wherein at least approximately 40% of the particles have a particle size of between 1 nm and approximately 750 nm.

25. The pharmaceutical composition of any of claims 19-24, wherein at least approximately 50% of the particles have a particle size of between 1 nm and approximately 750 nm.

26. The pharmaceutical composition of any of claims 19-25, wherein at least approximately 60% of the particles have a particle size of between 1 nm and approximately 750 nm.

27. The pharmaceutical composition of any of claims 19-26, wherein at least approximately 70% of the particles have a particle size of between 1 nm and approximately 750 nm.

28. The pharmaceutical composition of any of claims 19-27, wherein at least approximately 80% of the particles have a particle size of 310 between 1 nm and approximately 750 nm.

29. The pharmaceutical composition of any of claims 19-28, wherein at least approximately 90% of the particles have a particle size of between 1 nm and approximately 750 nm.

30. The pharmaceutical composition of any of claims 19-29, wherein at least approximately 95% of the particles have a particle size of between 1 nm and approximately 750 nm.

31. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a self-microemulsifying drug delivery system (SMEDDS).

32. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a self-emulsifying drug delivery system (SEDDS).

33. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a spray-dried dispersion dosage form.

34. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a hot granulation dosage form.

35. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a hot extrusion dosage form.

36. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a microprecipitated bulk powder (MBP) dosage form.

37. The pharmaceutical composition of any of claims 1-30, wherein the dosage form is a liquid.

38. The pharmaceutical composition of claim 37, wherein the dosage form is a suspension, solution, syrup, or elixir.

39. The pharmaceutical composition of claim 37 or 38, wherein the dosage form is a nanosuspension. 4.

0. The pharmaceutical composition of any of claims 37-39, wherein the dosage form is a suspension 41. The pharmaceutical composition of claim 40, wherein the dosage form is a colloidal suspension.

42. The pharmaceutical composition of any of claims 1-36, wherein the dosage form is a solid dosage form. 4 3. The pharmaceutical composition of any of claims 1-36 or 42, in 311 where the dosage form is a granule or powder.

4. The pharmaceutical composition of any of claims 1-36 or 42-43, wherein the dosage form is a tablet or a capsule.

45. The pharmaceutical composition of claim 44, wherein the tablet or capsule has an enteric coating. 4 6. The pharmaceutical composition of claim 44, wherein the dosage form is a tablet.

47. The pharmaceutical composition of claim 44, wherein the tablet is a floating osmotic tablet. 4 8. The pharmaceutical composition of claim 44, wherein the capsule is a hard capsule filled with liquid or a soft gelatin capsule.

49. The pharmaceutical composition of any of claims 1-48, wherein the dosage form is a modified-release dosage form.

50. The pharmaceutical composition of claim 49, wherein the modified-release dosage form is a delayed-release dosage form, an extended-release (ER) dosage form, or a targeted-release dosage form.

51. The pharmaceutical composition of claim 50, wherein the ER dosage form is a sustained-release (SR) dosage form or a controlled-release (CR) dosage form.

52. The pharmaceutical composition of any of claims 1-48, wherein the dosage form is an immediate-release dosage form 53. The pharmaceutical composition of any of claims 1-52, wherein the pharmaceutical composition comprises from approximately 10 mg to approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

54. The pharmaceutical composition of any of claims 1-52, wherein the pharmaceutical composition comprises from approximately 50 mg to approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

55. The pharmaceutical composition of any of claims 1-52, wherein the pharmaceutical composition comprises from approximately 50 mg and approximately 150 mg, approximately 150 mg and approximately 250 mg, approximately 250 mg and approximately 350 mg, approximately 350 mg and approximately 450 mg, approximately 450 mg and approximately 550 mg, approximately 550 mg and approximately 650 mg, approximately 650 mg and approximately 750 mg, approximately 850 mg and approximately 950 mg, or approximately 950 mg and approximately 1050 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

56. The pharmaceutical composition of any of claims 1-52, wherein the pharmaceutical composition comprises approximately 50 mg, approximately 100 mg, approximately 150 mg, approximately 200 mg, approximately 250 mg, approximately 300 mg, approximately 350 mg, approximately 400 mg, approximately 450 mg, approximately 500 mg, approximately 550 mg, approximately 600 mg, approximately 650 mg, approximately 700 mg, approximately 750 mg, approximately 800 mg, approximately 850 mg, approximately 900 mg, approximately 950 mg, or approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

57. The pharmaceutical composition of any of claims 1-52, wherein the pharmaceutical composition comprises approximately 50 mg, approximately 100 mg, approximately 150 mg, approximately 200 mg, approximately 250 mg, approximately 300 mg, approximately 350 mg, approximately 400 mg, or approximately 500 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

58. The pharmaceutical composition of any of claims 1-57, wherein the pharmaceutically acceptable excipient is a filler, a disintegrant, a binder, a lubricant, or any combination thereof.

59. The pharmaceutical composition of any of claims 1-58, wherein the pharmaceutically acceptable excipient is microcrystalline cellulose, pregelatinized starch, povidone, magnesium stearate, colloidal silicon dioxide, or any combination thereof.

60. The pharmaceutical composition of any of claims 1-59, wherein the pharmaceutical composition is stable for up to 36 months at a temperature between approximately 2 °C and approximately 25 °C.

61. The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is stable for a period of approximately 24 to approximately 36 months at a temperature of approximately 2°C to approximately 8°C.

62. The pharmaceutical composition of any of claims 1-61, wherein the pharmaceutical composition is substantially free from impurities.

63. The pharmaceutical composition of any of claims 1-62, wherein the pharmaceutical composition is at least approximately 90% pure.

64. The pharmaceutical composition of any of claims 1-63, wherein the pharmaceutical composition is at least approximately 95% pure.

65. The pharmaceutical composition of any of claims 1-64, wherein the pharmaceutical composition is at least approximately 96% pure.

66. The pharmaceutical composition of any of claims 1-65, wherein the pharmaceutical composition is at least approximately 97% pure.

67. The pharmaceutical composition of any of claims 1-66, wherein the pharmaceutical composition is at least approximately 98% pure.

68. The pharmaceutical composition of any of claims 1-67, wherein the pharmaceutical composition is at least approximately 99% pure.

69. The pharmaceutical composition of any of claims 1-68, wherein the pharmaceutical composition is at least approximately 99.1%, approximately 99.2%, approximately 99.3%, approximately 99.4%, approximately 99.5%, approximately 99.6%, approximately 99.7%, approximately 99.8%, approximately 99.9%, or approximately 100% pure.

70. The pharmaceutical composition of any of claims 1-62, wherein the pharmaceutical composition comprises up to approximately 10% (w / w) of at least one impurity.

71. The pharmaceutical composition of any of claims 1-62 or 70, wherein the pharmaceutical composition comprises less than approximately 10% (w / w), approximately 9% (w / w), approximately 8% (w / w), approximately 7% (w / w), approximately 6% (w / w), approximately 5% (w / w), approximately 4% (w / w), approximately 3% (w / w), approximately 2% (w / w), or approximately 1% (w / w) of at least one impurity.

72. The pharmaceutical composition of any of claims 1-62 or 70-71, wherein the pharmaceutical composition comprises less than approximately 5% (w / w), approximately 4% (w / w), approximately 3% (w / w), approximately 2% (w / w), or approximately 1% (w / w) of at least one impurity. 7 3. The pharmaceutical composition of any of claims 70-72, wherein the pharmaceutical composition comprises less than approximately 0.9% (w / w), approximately 0.8% (w / w), approximately 0.7% (w / w), approximately 0.6% (w / w), approximately 0.5% (w / w), approximately 0.4% (w / w), approximately 0.3% (w / w), approximately 0.2% (w / w), or approximately 0.1% (w / w) of at least one impurity. 7.

4. The pharmaceutical composition of any of claims 70-72, wherein the impurity is a degrading agent. 314 75. The pharmaceutical composition of any of claims 70-72, wherein the impurity is: 315 or any combination thereof. 7 6. The pharmaceutical composition of any one of claims 70-75, wherein the impurity is:

77. The pharmaceutical composition of any of claims 1-62, wherein the pharmaceutical composition comprises up to approximately 4.0% (w / w) total impurities. 7 8. The pharmaceutical composition of any of claims 1-62 or 77, wherein the pharmaceutical composition comprises up to approximately 0.5% (w / w) of any particular impurity. 7 9. The pharmaceutical composition of any of claims 1-62 or 77-78, wherein the pharmaceutical composition comprises up to approximately 1.5% (w / w) of the compound:

80. The pharmaceutical composition of any of claims 77-79, wherein the pharmaceutical composition comprises approximately 50 mg, approximately 100 mg, approximately 200 mg, approximately 300 mg, approximately 400 mg, or approximately 500 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

81. A pharmaceutical composition comprising: (i) a compound of Formula (I), hbhznn / ιζηζ / B / γι or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is in a dosage form for dosing or administration by injection.

82. The pharmaceutical composition of claim 81, wherein the pharmaceutical composition is in a dosage form for intravenous (IV) injection or infusion, or intramuscular, subcutaneous or intradermal injection.

83. The pharmaceutical composition of claim 82, wherein the pharmaceutical composition is in a dosage form for injection or IV infusion.

84. The pharmaceutical composition of any of claims 81-83, wherein the pharmaceutical composition is a solution.

85. The pharmaceutical composition of any of claims 81-84, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is crystalline, microcrystalline, amorphous, or lyophilized. 8 6. The pharmaceutical composition of claim 85, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is crystalline.

87. The pharmaceutical composition of claim 85, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is amorphous.

8. The pharmaceutical composition of claim 85, wherein the compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; is lyophilized.

89. The pharmaceutical composition of any of claims 81-88, wherein the dosage form comprises a cosolvent.

90. The pharmaceutical composition of claim 89, wherein the cosolvent comprises PEG200, PEG300, PEG400, PEG600, propylene glycol, ethanol, polysorbate 20, polysorbate 80, cremophor, glycerin, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), tert-butanol, or any combination thereof.

91. The pharmaceutical composition of any of claims 81-90, wherein the dosage form further comprises an oil.

92. The pharmaceutical composition of claim 91, wherein the oil comprises sesame oil, soybean oil, vegetable oil, poppy oil, safflower oil, or combinations thereof.

93. The pharmaceutical composition of any of claims 81-92, wherein the dosage form further comprises a buffer solution.

94. The pharmaceutical composition of claim 93, wherein the buffer solution is a phosphate regulator 95. The pharmaceutical composition of claim 94, wherein the phosphate regulator is potassium phosphate. 9 6. The pharmaceutical composition of claim 94 or 95, wherein the potassium phosphate is monobasic or dibasic.

97. The pharmaceutical composition of any of claims 81-96, wherein the pharmaceutical composition has a pH of between approximately 2.5 and approximately 11.

0.

98. The pharmaceutical composition of any of claims 81-96, wherein the pharmaceutical composition has a pH of between approximately 2.5 and approximately 5.0 or between approximately 6.5 and approximately 10.

5.

99. The pharmaceutical composition of any of claims 81-96, wherein the pharmaceutical composition has a pH of between approximately 2.5 and approximately 4.5 or between approximately 7.0 and approximately 9.

0.

100. The pharmaceutical composition of any of claims 81-99, wherein the pH of the pharmaceutical composition is adjusted with hydrochloric acid and / or sodium hydroxide.

101. The pharmaceutical composition of any of claims 81-100, wherein the pharmaceutical composition comprises from approximately 5 mg / mL to approximately 250 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

102. The pharmaceutical composition of any of claims 81-101, wherein the pharmaceutical composition comprises from approximately 10 mg / mL to approximately 50 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

103. The pharmaceutical composition of any of claims 81-102, wherein the pharmaceutical composition comprises from approximately 20 mg / mL to approximately 40 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

104. The pharmaceutical composition of any of claims 81-102, wherein the pharmaceutical composition comprises approximately 10 mg / mL, approximately 15 mg / mL, approximately 20 mg / mL, approximately 25 mg / mL, or approximately 30 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

105. The pharmaceutical composition of any of claims 1-104, wherein the pharmaceutical composition comprises from approximately 10 mg to approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

106. The pharmaceutical composition of any of claims 1-105, wherein the pharmaceutical composition comprises from approximately 50 mg to approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

107. The pharmaceutical composition of any of claims 1-105, wherein the pharmaceutical composition comprises from approximately 50 mg and approximately 150 mg, approximately 150 mg and approximately 250 mg, approximately 250 mg and approximately 350 mg, approximately 350 mg and approximately 450 mg, approximately 450 mg and approximately 550 mg, approximately 550 mg and approximately 650 mg, approximately 650 mg and approximately 750 mg, approximately 850 mg and approximately 950 mg, or approximately 950 mg and approximately 1050 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

108. The pharmaceutical composition of any of claims 81-105, wherein the pharmaceutical composition comprises approximately 50 mg, approximately 100 mg, approximately 150 mg, approximately 200 mg, approximately 250 mg, approximately 300 mg, approximately 350 mg, approximately 400 mg, approximately 450 mg, approximately 600 mg, approximately 750 mg, approximately 500 mg, approximately 650 mg, approximately 800 mg, approximately 550 mg, approximately 700 mg, approximately 850 mg, approximately 900 mg, approximately 950 mg, or approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

109. The pharmaceutical composition of any of claims 81-108, wherein the pharmaceutical composition is stable for up to approximately 24 months at a temperature of between approximately -20 °C and 8 °C.

110. The pharmaceutical composition of claim 101, wherein the pharmaceutical composition is stable for a period of approximately 12 to approximately 24 months at a temperature of approximately -20 °C.

111. The pharmaceutical composition of any of claims 81-110, wherein the pharmaceutical composition is substantially free from impurities.

112. The pharmaceutical composition of any of claims 81-111, wherein the pharmaceutical composition is at least approximately 90% pure.

113. The pharmaceutical composition of any of claims 81-112, wherein the pharmaceutical composition is at least approximately 95% pure.

114. The pharmaceutical composition of any of claims 81-113, wherein the pharmaceutical composition is at least approximately 96% pure.

115. The pharmaceutical composition of any of claims 81-114, wherein the pharmaceutical composition is at least approximately 97% pure.

116. The pharmaceutical composition of any of claims 81-115, wherein the pharmaceutical composition is at least approximately 98% pure.

117. The pharmaceutical composition of any of claims 81-116, wherein the pharmaceutical composition is at least approximately 99% pure.

118. The pharmaceutical composition of any of claims 81-117, wherein the pharmaceutical composition is at least approximately 99.1%, approximately 99.2%, approximately 99.3%, approximately 99.4%, approximately 99.5%, approximately 99.6%, approximately 99.7%, approximately 99.8%, approximately 99.9%, or approximately 100% pure.

119. The pharmaceutical composition of any of claims 81-111, wherein the pharmaceutical composition comprises up to approximately 10% (w / w) of at least one impurity. 12 0. The pharmaceutical composition of any of claims 81-111 or 119, wherein the pharmaceutical composition comprises less than approximately 10% (w / w), approximately 9% (ρ / ρ), approximately 8% (ρ / ρ), approximately 7% (ρ / ρ), approximately 6% (ρ / ρ), approximately 5% (ρ / ρ), approximately 4% (ρ / ρ), approximately 3% (ρ / ρ), approximately 2% (ρ / ρ), or approximately 1% (w / w) of at least one impurity.

121. The pharmaceutical composition of any of claims 81-111 or 119-120, wherein the pharmaceutical composition comprises less than approximately 5% (w / w), approximately 4% (w / w), approximately 3% (w / w), approximately 2% (w / w), or approximately 1% (w / w) of at least one impurity.

122. The pharmaceutical composition of any of claims 81-111 or 119-121, wherein the pharmaceutical composition comprises less than approximately 0.9% (w / w), approximately 0.8% (w / w), approximately 0.7% (w / w), approximately 0.6% (w / w), approximately 0.5% (w / w), approximately 0.4% (w / w), approximately 0.3% (w / w), approximately 0.2% (w / w), or approximately 0.1% (w / w) of at least one impurity. 12 3. The pharmaceutical composition of any of claims 119-122, wherein the impurity is a degradant.

124. The pharmaceutical composition of any of claims 119-123, wherein the impurity is: 321 or any combination thereof. 5 12 5. The pharmaceutical composition of any of claims 119-124, wherein the impurity is: 12 6. The pharmaceutical composition of any of claims 81-111, wherein the pharmaceutical composition comprises up to approximately 4.0% (w / w) total impurities. 322 127. The pharmaceutical composition of any of claims 81-111 or 126, wherein the pharmaceutical composition comprises up to approximately 0.5% (w / w) of any particular impurity. 12 8. The pharmaceutical composition of any of claims 81-111 or 126-127, wherein the pharmaceutical composition comprises up to approximately 1.5% (w / w) of the compound: 12 9. The pharmaceutical composition of any of claims 81-128, wherein the pharmaceutical composition comprises approximately 20 mg / mL of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

130. A combined composition comprising: (i) a compound of Formula (I): or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one antifungal agent.

131. L of claim 130, wherein the composition further comprises at least one pharmaceutically acceptable excipient.

132. The composition of claim 130 or 131, wherein the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof. 323 133. The composition of claim 132, wherein the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole.

134. The composition of claim 132, wherein the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin.

135. A combined composition, comprising: (i) a compound of Formula (I): hbh7nn / LZnZ / B / Yli or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a compound of Formula (II) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

136. The composition of claim 135, wherein the composition further comprises at least one pharmaceutically acceptable excipient.

137. The composition of claim 135 or 136, wherein the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and the compound of Formula (II), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, are both crystalline.

138. The composition of any of claims 135-137, wherein the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and the compound of Formula (II), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, are present in a ratio of approximately 10:

1. 324 139. The composition of any of claims 135-138, wherein the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof and the compound of Formula (II), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof are present in a ratio of between approximately 9:1 and approximately 9.99:0.

01.

140. The composition of any of claims 135-139, wherein the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and the compound of Formula (II), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, are present in a ratio of between approximately 9.5:0.5 and approximately 9.9:0.

1.

141. The composition of any of claims 135-140, wherein the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and the compound of Formula (II), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, are present in a ratio of approximately 9:1, approximately 9.1:0.9, approximately 9.2:0.8, approximately 9.3:0.7, approximately 9.4:0.6, approximately 9.5:0.5, approximately 9.6:0.4, approximately 9.7:0.3, approximately 9.8:0.2, or approximately 9.9:0.

1.

142. A method of treating or preventing a fungal infection or disease, comprising administering to a subject in need a therapeutically effective amount of the pharmaceutical composition of any of claims 1-129 or the composition of any of claims 130-141.

143. The method of claim 142, wherein the subject is administered between approximately 10 mg and approximately 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

144. The method of claim 142 or 143, wherein the subject is administered between approximately 10 mg and approximately 2,400 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

145. The method of any of claims 142-144, wherein the subject is administered between approximately 10 mg and approximately 2,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. 14 6. The method of any of claims 142-144, wherein the subject is administered approximately 10 mg, approximately 30 mg, approximately 50 mg, approximately 325 mg, approximately 100 mg, approximately 150 mg, approximately 200 mg, approximately 275 mg, approximately 300 mg, approximately 350 mg, approximately 400 mg, approximately 500 mg, approximately 600 mg, approximately 700 mg, approximately 800 mg, approximately 900 mg, approximately 1,000 mg, approximately 1,200 mg, approximately 1,500 mg, approximately 1,800 mg, approximately 2,000 mg, approximately 2,100 mg, approximately 2,400 mg, approximately 2,500 mg, approximately 3,000 mg, approximately 4,000 mg, approximately 5,000 mg, approximately 6,000 mg, approximately 7,000 mg, or approximately 8,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

147. The method of any one of claims 142-146, wherein approximately 40 mg, approximately 50 mg, approximately 100 mg, approximately 200 mg, approximately 250 mg, approximately 350 mg, approximately 400 mg, approximately 500 mg, approximately 600 mg, approximately 700 mg, approximately 800 mg, or approximately 900 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

148. The method of any of claims 142-144, wherein approximately 600 mg, approximately 700 mg, approximately 800 mg, approximately 900 mg, 1,000 mg, approximately 2,000 mg, or approximately 3,000 mg of the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered to the subject.

149. The method of any of claims 142-148, wherein the pharmaceutical composition is administered to the subject daily.

150. The method of any of claims 142-149, wherein the pharmaceutical composition is administered to the subject once a day, twice a day, three times a day, or four times a day.

151. The method of any of claims 142-150, wherein the pharmaceutical composition is administered to the subject for a period of up to approximately 12 weeks.

152. The method of any of claims 142-151, wherein the pharmaceutical composition is administered to the subject for a period of at least one week.

153. The method of any of claims 142-152, wherein the pharmaceutical composition is administered to the subject for a period of at least two 32 6 weeks.

154. The method of any of claims 142-153, wherein the pharmaceutical composition is administered to the subject for a period of one week, two weeks, six weeks, twelve weeks, twenty-four weeks, forty-eight weeks, or fifty-two weeks.

155. The method of any of claims 142-154, wherein the pharmaceutical composition is administered to the subject for a period of approximately 20 minutes, approximately 30 minutes, approximately 60 minutes, approximately 90 minutes, approximately 2 hours, approximately 3 hours, approximately 4 hours, approximately 5 hours, approximately 6 hours, approximately 7 hours, approximately 8 hours, approximately 9 hours, approximately 10 hours, approximately 12 hours, approximately 18 hours, or approximately 24 hours by IV infusion.

156. The method of any of claims 142-155, wherein the pharmaceutical composition is administered to the subject for a period of up to approximately 3 hours by IV infusion.

157. The method of any of claims 142-156, wherein the subject is administered a loading dose followed by a maintenance dose.

158. The method of claim 157, wherein the loading dose comprises from approximately 1,000 mg to approximately 8,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

159. The method of claim 157 or 158, wherein the maintenance dose comprises from approximately 600 mg to approximately 2,400 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

160. The method of any of claims 157-159, wherein the loading dose comprises between approximately 1,000 mg and approximately 2,000 mg.

161. The method of any of claims 157-160, wherein the loading dose is administered over a period of approximately 2 and approximately 3 hours by IV infusion.

162. The method of any of claims 157-161, wherein the loading dose is administered twice during the first day of treatment.

163. The method of claim 162, wherein the second loading dose is administered approximately 9 hours after the first loading dose.

164. The method of any of claims 157-163, wherein the maintenance dose comprises approximately 600 mg, approximately 700 mg, approximately 800 mg, approximately 900 mg, or approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

165. The method of any of claims 157-164, wherein the maintenance dose comprises approximately 800 mg or approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, administered to the subject.

166. The method of any of claims 157-164, wherein the maintenance dose comprises approximately 600 mg or approximately 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof.

167. The method of any of claims 157-164, wherein the maintenance dose comprises approximately 600 mg or approximately 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, and is administered orally.

168. The method of any of claims 157-164, wherein the maintenance dose comprises approximately 600 mg or approximately 900 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered over a period of approximately 1 hour and approximately 3 hours by IV infusion.

169. The method of any one of claims 157-164, wherein approximately 600 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered over a period of approximately 3 hours by IV infusion 17 0. The method of any of claims 157-169, wherein the maintenance dose is administered once a day.

171. The method of any of claims 157-170, wherein the maintenance dose is administered once a day starting from the second day of treatment.

172. The method of any of claims 157-164, wherein approximately 600 mg or approximately 800 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered over a period of approximately 3 hours by IV infusion starting on the second, third, or fourth day of treatment.

173. The method of any of claims 157-164, wherein approximately 800 mg or approximately 1,000 mg of a compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered orally starting on the second, third, or fourth day of treatment.

174. The method of any of claims 142-173, wherein the fungal infection is caused by an invasive fungus.

175. The method of any of claims 142-174, wherein it further comprises administering to the subject at least one antifungal agent in combination with the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof. 17 6. The method of claim 175, wherein the antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof.

177. The method of claim 176, wherein the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole.

178. The method of claim 177, wherein the echinocandin is caspofungin, anidulafungin, micafungin, or rezafungin, or combinations thereof. 17 9. The method of any of claims 175-178, wherein the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously, approximately simultaneously, or sequentially, in any order.

180. The method of claim 179, wherein the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered simultaneously or approximately simultaneously.

181. The method of claim 179, wherein the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and the antifungal agent are administered sequentially.

182. The method of claim 181, wherein the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered prior to the antifungal agent.

183. The method of claim 181, wherein the pharmaceutical composition comprising the compound of Formula (I), or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; or a pharmaceutically acceptable salt thereof, is administered after the antifungal agent. 32 9 18 4 . The method of any of claims 142-183, wherein the fungal infection or disease is caused by a fungus of the order Aspergillus fumigatus, Blastomyces, Ajellomyces, Candida, Coccidioides, Cryptococcus, Histoplasma, Rhizopus Muco, Cunninghamell, Apophysomyces, Absidi, Saksenaea, Entomophthora, Conidiobolus, Basidiobolus, Sporothrix, Pneumocystis, Talaromyces, Asclepias, Fusarium, Scedosporium or by a fungus of the order Mucorales, or any combination thereof.

185. The method of any of claims 142-183, wherein the fungal infection or disease is caused by a fungus Cryptococcus, Aspergillus, Candida, Fusarium, Scedosporium or by a fungus of the order Mucorales, or any combination thereof. 18 6. The method of claim 185, wherein the fungal infection or disease is caused by Aspergillus fumigatus, Aspergillus flavus, Blastomyces dermatitidis, Ajellomyces dermatitidi, Candida albican, Candida glabrata, Candida rugosa, Candida auris, Coccidioides immitis, Coccidioides posadasii, Cryptococcus neoformans, Cryptococcus gattii, Histoplasma capsulatum, Rhizopus stolonifer, Rhizopus arrhizus, Mucor indicus, Cunninghamella bertholletiae, Apophysomyces elegans, Absidia species, Saksenaea species, Rhizomucor pusillus, Entomophthora species, Conidiobolus species, Basidiobolus species, Sporothrix schenckii, Pneumocystis jirovecii, Talaromyces marneffei, Asclepias albicans, Fusarium solani, Scedosporium apiospermum, Rhizomucor pusillus, or any of their combinations.

187. The method of claim 185, wherein the fungal infection or disease is caused by a Cryptococcus fungus or a Candida fungus.

188. The method of claim 187, wherein the fungal infection or disease is caused by Cryptococcus neoformans, Cryptococcus gattii, or Candida auris. 18 9. The method of any of claims 142-188, wherein the fungal infection or disease is azole-resistant and / or echinocandin-resistant.

190. The method of any of claims 142-189, wherein the subject is immunocompromised.

191. The method of any of claims 142-190, wherein the subject is infected with HIV / AIDS or has cancer.

192. The method of claim 191, wherein the subject has cancer.

193. The method of claim 192, wherein the cancer is acute myeloid leukemia (AML).

194. The method of any of claims 142-193, wherein the subject has neutropenia.

195. The method of any of claims 142-194, wherein the subject is or has been under chemotherapy treatment for cancer.

196. The method of any of claims 142-190, wherein the subject is or has been under treatment with corticosteroids.

197. The method of any of claims 142-190, wherein the subject is or has been under treatment with TNF inhibitors.

198. The method of any of claims 142-190, wherein the subject is the recipient of a transplant.

199. The method of any of claims 142-198, wherein the fungal infection or disease is in the bloodstream of the subject.

200. The method of any of claims 142-199, wherein the subject has a reduced count of fungal colonies in the lungs after administration of the pharmaceutical composition. 2 01. The method of any of claims 142-200, wherein the plasma concentration versus time curve of the compound of Formula (I) in the subject has a tmax of less than between approximately 30 minutes and approximately 180 minutes. 2.

02. The method of any of claims 142-201, wherein the subject has a maximum plasma concentration (Cmax) of between approximately 12,000 ng / mL and approximately 25,000 ng / mL of the compound of Formula (I).